2,2',5,5'-tetrachlorobiphenyl - Ontology Report - Rat Genome Database

	Submit Data \| Help \| Video Tutorials \| News \| Publications \| FTP Download \| REST API \| Citing RGD \| Contact
	Search RGD Grant Resources Citing RGD About Us Contact Us Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References FTP Download Submit Data OntoMate (Literature Search) JBrowse (Genome Browser) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) RatMine GViewer (Genome Viewer) Overgo Probe Designer ACP Haplotyper Genome Scanner Aging & Age-Related Disease Cancer Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease Find Models new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive Pathways Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
	Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	2,2',5,5'-tetrachlorobiphenyl	go back to main search page
Accession:	CHEBI:34206	browse the term
Definition:	A tetrachlorobiphenyl that is biphenyl in which the hydrogens at the 2 and 5 position of each benzene ring are replaced by chlorines.
Synonyms:	exact_synonym:	2,2',5,5'-tetrachloro-1,1'-biphenyl
	related_synonym:	2,2',5,5'-TCB; 2,3',5,6'-tetrachlorobiphenyl; Formula=C12H6Cl4; InChI=1S/C12H6Cl4/c13-7-1-3-11(15)9(5-7)10-6-8(14)2-4-12(10)16/h1-6H; InChIKey=HCWZEPKLWVAEOV-UHFFFAOYSA-N; PCB 52; SMILES=Clc1ccc(Cl)c(c1)-c1cc(Cl)ccc1Cl
	xref:	Beilstein:2053828; CAS:35693-99-3; KEGG:C14199
	xref_mesh:	MESH:C009407

show annotations for term's descendants Sort by:

Rat (1730) Mouse (1850) Human (1718) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) All
Genes (1730)

2,2',5,5'-tetrachlorobiphenyl

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 13

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ABCA13 mRNA

NCBI chr14:89,384,512...89,876,748
Ensembl chr14:89,384,512...89,714,917

G

ATP binding cassette subfamily B member 1A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ABCB1A mRNA

NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515

G

ATP binding cassette subfamily C member 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ABCC2 mRNA

NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252

G

ATP binding cassette subfamily C member 3

multiple interactions

[2,5,2',5'-tetrachlorobiphenyl co-treated with 2,2',3,5',6-pentachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,3,3',4',6-pentachlorobiphenyl co-treated with 2,3',4,4',5-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl] results in increased expression of ABCC3 mRNA

NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109

G

ATP binding cassette subfamily G member 5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ABCG5 mRNA

NCBI chr 6:7,935,771...7,961,207
Ensembl chr 6:7,935,771...7,961,207

G

abhydrolase domain containing 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ABHD1 mRNA

NCBI chr 6:26,787,807...26,792,795
Ensembl chr 6:26,784,058...26,792,808

G

actin-binding LIM protein 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ABLIM1 mRNA

NCBI chr 1:277,853,877...278,043,096

G

ABR activator of RhoGEF and GTPase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ABR mRNA

NCBI chr10:64,565,121...64,657,079
Ensembl chr10:64,567,268...64,657,089

G

acetyl-CoA carboxylase beta

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ACACB mRNA

NCBI chr12:48,127,149...48,238,969
Ensembl chr12:48,127,149...48,238,887

G

acyl-CoA dehydrogenase family, member 9

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of ACAD9 mRNA

NCBI chr 2:122,782,051...122,806,166
Ensembl chr 2:122,782,060...122,805,768

G

acyl-CoA dehydrogenase short chain

increases expression
affects expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of ACADS mRNA
2,5,2',5'-tetrachlorobiphenyl affects the expression of ACADS mRNA

NCBI chr12:47,254,503...47,263,747
Ensembl chr12:47,254,484...47,263,747

G

alkaline ceramidase 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ACER1 mRNA

NCBI chr 9:10,061,978...10,093,588
Ensembl chr 9:10,061,978...10,093,588

G

acetylcholinesterase

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of ACHE mRNA

NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753

G

acyl-CoA thioesterase 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ACOT4 mRNA

NCBI chr 6:107,517,668...107,522,952
Ensembl chr 6:107,517,668...107,522,952

G

acyl-CoA oxidase 3, pristanoyl

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ACOX3 mRNA

NCBI chr14:80,313,202...80,358,115
Ensembl chr14:80,314,431...80,355,420

G

acid phosphatase 7, tartrate resistant

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ACP7 mRNA

NCBI chr 1:85,141,383...85,162,449
Ensembl chr 1:85,143,789...85,153,210

G

acrosin binding protein

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ACRBP mRNA

NCBI chr 4:157,563,990...157,577,045
Ensembl chr 4:157,563,990...157,568,023

G

acyl-CoA synthetase long-chain family member 6

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ACSL6 mRNA

NCBI chr10:39,654,771...39,717,592
Ensembl chr10:39,655,455...39,719,312

G

acyl-CoA synthetase short-chain family member 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ACSS3 mRNA

NCBI chr 7:49,047,022...49,250,953
Ensembl chr 7:49,047,013...49,250,957

G

actin, beta-like 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ACTBL2 mRNA

NCBI chr 2:42,829,413...42,832,160
Ensembl chr 2:42,829,413...42,832,160

G

actin, alpha, cardiac muscle 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ACTC1 mRNA

NCBI chr 3:105,507,403...105,512,939
Ensembl chr 3:105,507,403...105,512,939

G

actin related protein 3B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ACTR3B mRNA

NCBI chr 4:5,644,287...5,672,708
Ensembl chr 4:5,644,260...5,672,708

G

activin A receptor type 2B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ACVR2B mRNA

NCBI chr 8:128,087,308...128,126,776
Ensembl chr 8:128,087,345...128,118,746

G

ADAM metallopeptidase domain 12

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ADAM12 mRNA

NCBI chr 1:205,951,840...206,286,294
Ensembl chr 1:205,956,342...206,282,575

G

ADAM metallopeptidase domain 22

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ADAM22 mRNA

NCBI chr 4:22,864,485...23,002,969
Ensembl chr 4:22,859,622...22,996,645

G

ADAM metallopeptidase domain 32

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ADAM32 mRNA

NCBI chr16:71,889,035...71,999,151
Ensembl chr16:71,889,235...71,999,148

G

ADAM metallopeptidase domain 8

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ADAM8 mRNA

NCBI chr 1:212,317,510...212,332,895
Ensembl chr 1:212,317,848...212,330,349

G

ADAM metallopeptidase with thrombospondin type 1 motif, 7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ADAMTS7 mRNA

NCBI chr 8:97,535,777...97,575,661
Ensembl chr 8:97,535,777...97,575,655

G

adenosine deaminase, tRNA-specific 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ADAT2 mRNA

NCBI chr 1:7,726,447...7,743,112
Ensembl chr 1:7,726,529...7,742,484

G

adenylate cyclase 10

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ADCY10 mRNA

NCBI chr13:83,701,952...83,787,010
Ensembl chr13:83,721,300...83,787,018

G

adenylate cyclase 5

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of ADCY5 mRNA

NCBI chr11:68,695,839...68,842,452
Ensembl chr11:68,695,839...68,842,320

G

adhesion G protein-coupled receptor F5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ADGRF5 mRNA

NCBI chr 9:20,091,121...20,195,706
Ensembl chr 9:20,091,099...20,195,566

G

adhesion G protein-coupled receptor G3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ADGRG3 mRNA

NCBI chr19:10,392,001...10,422,606
Ensembl chr19:10,392,004...10,421,010

G

adhesion G protein-coupled receptor L4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ADGRL4 mRNA

NCBI chr 2:256,609,787...256,724,642
Ensembl chr 2:256,609,787...256,724,641

G

alcohol dehydrogenase, iron containing, 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ADHFE1 mRNA

NCBI chr 5:9,403,194...9,429,783
Ensembl chr 5:9,403,196...9,429,859

G

adiponectin, C1Q and collagen domain containing

affects expression
multiple interactions

2,5,2',5'-tetrachlorobiphenyl affects the expression of ADIPOQ mRNA
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ADIPOQ mRNA

PMID:21703328 PMID:25510870

NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488

G

adrenomedullin 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ADM2 mRNA

NCBI chr 7:130,296,895...130,298,641
Ensembl chr 7:130,296,897...130,298,644

G

adrenoceptor alpha 1B

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of ADRA1B mRNA

NCBI chr10:29,392,762...29,450,644
Ensembl chr10:29,392,762...29,450,644

G

adhesion regulating molecule 1

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of ADRM1 mRNA

NCBI chr 3:175,548,181...175,552,943
Ensembl chr 3:175,548,174...175,552,947

G

actin filament associated protein 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AFAP1 mRNA

NCBI chr14:79,923,132...80,035,096
Ensembl chr14:79,919,717...79,988,110

G

ArfGAP with GTPase domain, ankyrin repeat and PH domain 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AGAP2 mRNA

NCBI chr 7:70,360,199...70,377,422
Ensembl chr 7:70,364,813...70,377,422

G

ATP/GTP binding protein-like 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AGBL2 mRNA

NCBI chr 3:79,622,791...79,647,402
Ensembl chr 3:79,613,171...79,646,698

G

angiogenic factor with G patch and FHA domains 1

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of AGGF1 mRNA

NCBI chr 2:25,068,804...25,095,429
Ensembl chr 2:25,069,620...25,095,106

G

argonaute RISC component 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AGO4 mRNA

NCBI chr 5:144,501,875...144,557,165
Ensembl chr 5:144,504,938...144,556,889

G

angiotensin II receptor, type 1a

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AGTR1A mRNA

NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077

G

alanine-glyoxylate aminotransferase 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AGXT2 mRNA

NCBI chr 2:60,337,667...60,379,144
Ensembl chr 2:60,337,667...60,379,420

G

adenosylhomocysteinase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AHCY mRNA

NCBI chr 3:150,587,833...150,603,057
Ensembl chr 3:150,587,833...150,603,082

G

aryl hydrocarbon receptor

multiple interactions

2,5,2',5'-tetrachlorobiphenyl binds to and results in decreased activity of AHR protein; 2,5,2',5'-tetrachlorobiphenyl inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of and results in increased localization of AHR protein]

PMID:12051995 PMID:12628580

NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464

G

aryl hydrocarbon receptor-interacting protein-like 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AIPL1 mRNA

NCBI chr10:58,599,690...58,631,194
Ensembl chr10:58,599,856...58,608,907

G

adherens junctions associated protein 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AJAP1 mRNA

NCBI chr 5:170,615,885...170,679,315
Ensembl chr 5:170,615,886...170,679,315

G

adenylate kinase 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AK1 mRNA

NCBI chr 3:11,652,143...11,659,135

G

A-kinase anchoring protein 10

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AKAP10 mRNA

NCBI chr10:48,150,902...48,210,074
Ensembl chr10:48,150,902...48,210,074

G

A-kinase anchoring protein 9

decreases expression
multiple interactions

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of AKAP9 mRNA
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AKAP9 mRNA

PMID:23829299 PMID:25510870

NCBI chr 4:27,195,346...27,331,582
Ensembl chr 4:27,195,346...27,331,582

G

aldo-keto reductase family 1, member B7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AKR1B7 mRNA

NCBI chr 4:61,850,256...61,879,733
Ensembl chr 4:61,850,348...61,862,526

G

AKT serine/threonine kinase 2

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of AKT2 mRNA

NCBI chr 1:84,400,939...84,451,223
Ensembl chr 1:84,411,726...84,450,162

G

AKT serine/threonine kinase 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AKT3 mRNA

NCBI chr13:95,076,308...95,348,913
Ensembl chr13:95,081,390...95,348,913

G

AKT interacting protein

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of AKTIP mRNA

NCBI chr19:17,290,048...17,300,054
Ensembl chr19:17,290,178...17,300,050

G

aldehyde dehydrogenase 18 family, member A1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ALDH18A1 mRNA

NCBI chr 1:259,641,673...259,674,521
Ensembl chr 1:259,641,676...259,674,425
Ensembl chr 1:259,641,676...259,674,425

G

aldehyde dehydrogenase 6 family, member A1

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of ALDH6A1 mRNA

NCBI chr 6:108,146,552...108,167,185
Ensembl chr 6:108,146,582...108,167,185

G

ALG13, UDP-N-acetylglucosaminyltransferase subunit

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ALG13 mRNA

NCBI chr X:115,561,329...115,589,792
Ensembl chr X:115,561,332...115,619,505

G

alkB homolog 8, tRNA methyltransferase

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of ALKBH8 mRNA

NCBI chr 6:18,877,885...18,952,773
Ensembl chr 6:18,877,907...18,949,393

G

alkaline phosphatase, biomineralization associated

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of ALPL mRNA

NCBI chr 5:156,086,496...156,141,513
Ensembl chr 5:156,086,497...156,141,537

G

alsin Rho guanine nucleotide exchange factor ALS2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ALS2 mRNA

NCBI chr 9:65,961,361...66,034,396
Ensembl chr 9:65,961,346...66,033,871

G

APC membrane recruitment protein 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AMER3 mRNA

NCBI chr 9:41,089,417...41,101,108
Ensembl chr 9:41,096,835...41,099,189

G

anti-Mullerian hormone

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AMH mRNA

NCBI chr 7:11,775,155...11,777,503
Ensembl chr 7:11,775,155...11,777,503

G

angiopoietin-like 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANGPTL3 mRNA

NCBI chr 5:117,698,590...117,706,729
Ensembl chr 5:117,698,764...117,705,808

G

ankyrin 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANK1 mRNA

NCBI chr16:73,681,422...73,912,605
Ensembl chr16:73,681,422...73,827,488

G

ankyrin 3

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of ANK3 mRNA

NCBI chr20:19,948,767...20,480,628
Ensembl chr20:20,105,047...20,480,623

G

ankyrin repeat and LEM domain containing 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ANKLE1 mRNA

NCBI chr16:19,799,943...19,826,057
Ensembl chr16:19,800,463...19,803,796

G

ankyrin repeat domain 12

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANKRD12 mRNA

NCBI chr 9:113,605,683...113,682,482
Ensembl chr 9:113,605,657...113,682,482

G

ankyrin repeat domain 22

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANKRD22 mRNA

NCBI chr 1:252,430,750...252,461,346
Ensembl chr 1:252,429,677...252,461,461

G

ankyrin repeat domain 34A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANKRD34A mRNA

NCBI chr 2:198,720,277...198,725,155
Ensembl chr 2:198,721,724...198,725,154

G

ankyrin repeat domain 34B

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of ANKRD34B mRNA

NCBI chr 2:22,000,106...22,016,764
Ensembl chr 2:22,000,106...22,016,030

G

ankyrin repeat domain 40

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANKRD40 mRNA

NCBI chr10:82,032,656...82,045,937
Ensembl chr10:82,032,656...82,045,935

G

ankyrin repeat and sterile alpha motif domain containing 1B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANKS1B mRNA

NCBI chr 7:30,507,135...31,684,604
Ensembl chr 7:30,699,476...31,681,182

G

anoctamin 10

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANO10 mRNA

NCBI chr 8:130,812,941...130,931,021
Ensembl chr 8:130,813,214...130,930,990

G

anoctamin 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANO3 mRNA

NCBI chr 3:101,843,516...102,203,368
Ensembl chr 3:101,840,630...102,151,489

G

ANTXR cell adhesion molecule 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ANTXR2 mRNA

NCBI chr14:13,191,716...13,331,286
Ensembl chr14:13,192,347...13,274,978

G

adaptor related protein complex 4 subunit epsilon 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AP4E1 mRNA

NCBI chr 3:119,484,714...119,548,491
Ensembl chr 3:119,484,677...119,548,621

G

APC regulator of WNT signaling pathway 2

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of APC2 mRNA

NCBI chr 7:12,258,468...12,280,459
Ensembl chr 7:12,258,468...12,275,609

G

apolipoprotein B receptor

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of APOBR mRNA

NCBI chr 1:197,999,209...198,003,839
Ensembl chr 1:197,999,037...198,003,839

G

apolipoprotein D

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of APOD mRNA

NCBI chr11:72,705,204...72,726,263
Ensembl chr11:72,705,129...72,726,301

G

apolipoprotein E

affects expression

2,5,2',5'-tetrachlorobiphenyl affects the expression of APOE mRNA

NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057

G

amyloid beta precursor protein

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180 co-treated with APP protein modified form] results in decreased expression of DLG4 protein; [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180 co-treated with APP protein modified form] results in decreased expression of SYP protein

NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858

G

aquaporin 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AQP1 mRNA

NCBI chr 4:85,551,503...85,563,683
Ensembl chr 4:85,551,502...85,569,360

G

aquaporin 3 (Gill blood group)

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of AQP3 mRNA

NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245

G

androgen receptor

multiple interactions

2,5,2',5'-tetrachlorobiphenyl inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]

NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026

G

ADP-ribosylation factor GTPase activating protein 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ARFGAP1 mRNA

NCBI chr 3:176,475,847...176,490,642
Ensembl chr 3:176,475,893...176,489,925

G

Rho GTPase activating protein 11A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ARHGAP11A mRNA

NCBI chr 3:105,281,827...105,298,108
Ensembl chr 3:105,281,827...105,298,108

G

Rho GTPase activating protein 20

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of ARHGAP20 mRNA

NCBI chr 8:56,179,581...56,264,343
Ensembl chr 8:56,179,637...56,264,263

G

Rho GTPase activating protein 26

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ARHGAP26 mRNA

NCBI chr18:31,807,052...32,557,176
Ensembl chr18:31,812,109...32,207,801

G

Rho guanine nucleotide exchange factor 10

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of ARHGEF10 mRNA

NCBI chr16:79,725,629...79,817,065
Ensembl chr16:79,725,643...79,793,619

G

Rho guanine nucleotide exchange factor 15

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ARHGEF15 mRNA

NCBI chr10:55,532,097...55,545,675
Ensembl chr10:55,532,077...55,544,429

G

Rho guanine nucleotide exchange factor 33

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ARHGEF33 mRNA

NCBI chr 6:2,982,324...3,100,358
Ensembl chr 6:3,012,804...3,095,500

G

Rho guanine nucleotide exchange factor 37

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ARHGEF37 mRNA

NCBI chr18:56,817,986...56,871,159
Ensembl chr18:56,817,988...56,870,839

G

Rho guanine nucleotide exchange factor 38

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ARHGEF38 mRNA

NCBI chr 2:238,274,040...238,370,401
Ensembl chr 2:238,276,045...238,369,692

G

Rho guanine nucleotide exchange factor 39

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ARHGEF39 mRNA

NCBI chr 5:58,998,209...59,001,779
Ensembl chr 5:58,995,249...59,001,800

G

Rho guanine nucleotide exchange factor 4

affects expression

2,5,2',5'-tetrachlorobiphenyl affects the expression of ARHGEF4 mRNA

NCBI chr 9:41,160,562...41,305,015
Ensembl chr 9:41,295,909...41,302,501

G

Rho guanine nucleotide exchange factor 5

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of ARHGEF5 mRNA

NCBI chr 4:72,710,775...72,736,415
Ensembl chr 4:72,718,458...72,735,007

G

Rho guanine nucleotide exchange factor 7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ARHGEF7 mRNA

NCBI chr16:83,006,732...83,117,065
Ensembl chr16:83,006,718...83,132,785

G

AT-rich interaction domain 1A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ARID1A mRNA

NCBI chr 5:151,904,687...151,977,973
Ensembl chr 5:151,904,684...151,977,636

G

AT-rich interaction domain 5B

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of ARID5B mRNA

NCBI chr20:21,713,900...21,881,193
Ensembl chr20:21,564,975...21,880,715

G

ADP-ribosylation factor like GTPase 16

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ARL16 mRNA

NCBI chr10:109,636,770...109,639,018
Ensembl chr10:109,636,896...109,639,054

G

aryl hydrocarbon receptor nuclear translocator-like 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ARNTL2 mRNA

NCBI chr 4:181,103,774...181,158,415
Ensembl chr 4:181,103,774...181,214,994

G

arylsulfatase family, member J

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ARSJ mRNA

NCBI chr 2:230,163,014...230,662,084

G

ADP-ribosyltransferase 3

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of ART3 mRNA

NCBI chr14:17,143,037...17,225,389
Ensembl chr14:17,143,040...17,225,389

G

ADP-ribosyltransferase 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ART4 mRNA

NCBI chr 4:170,830,851...170,841,187
Ensembl chr 4:170,830,851...170,841,187

G

ARVCF, delta catenin family member

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ARVCF mRNA

NCBI chr11:86,736,125...86,793,795
Ensembl chr11:86,736,142...86,793,791

G

ankyrin repeat and SOCS box-containing 16

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ASB16 mRNA

NCBI chr10:90,217,979...90,224,984
Ensembl chr10:90,217,924...90,226,537

G

activating signal cointegrator 1 complex subunit 3

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of ASCC3 mRNA

NCBI chr20:55,253,670...55,557,249
Ensembl chr20:55,253,686...55,556,473

G

anti-silencing function 1B histone chaperone

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ASF1B mRNA

NCBI chr19:25,077,918...25,092,491
Ensembl chr19:25,077,918...25,092,491

G

asialoglycoprotein receptor 2

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of ASGR2 mRNA

NCBI chr10:56,710,446...56,723,608
Ensembl chr10:56,710,464...56,723,611

G

acid sensing ion channel subunit 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ASIC2 mRNA

NCBI chr10:68,247,800...69,347,223
Ensembl chr10:68,248,655...68,517,564

G

acid sensing ion channel subunit family member 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ASIC4 mRNA

NCBI chr 9:82,647,071...82,668,920
Ensembl chr 9:82,647,071...82,668,920

G

aspartoacylase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ASPA mRNA

NCBI chr10:59,839,693...59,888,244
Ensembl chr10:59,839,852...59,892,960

G

aspartate-beta-hydroxylase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ASPH mRNA

NCBI chr 5:22,577,680...22,799,333
Ensembl chr 5:22,577,675...22,799,349

G

assembly factor for spindle microtubules

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ASPM mRNA

NCBI chr13:56,546,021...56,591,793
Ensembl chr13:56,546,021...56,591,793

G

ASXL transcriptional regulator 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ASXL3 mRNA

NCBI chr18:13,322,148...13,496,230
Ensembl chr18:13,386,133...13,491,735

G

ATPase family, AAA domain containing 2B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ATAD2B mRNA

NCBI chr 6:28,998,080...29,066,850
Ensembl chr 6:29,012,007...29,163,134

G

ATPase family, AAA domain containing 5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ATAD5 mRNA

NCBI chr10:67,427,042...67,475,825
Ensembl chr10:67,427,066...67,473,649

G

ATM serine/threonine kinase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ATM mRNA; [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ATM protein

NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045

G

atonal bHLH transcription factor 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ATOH1 mRNA

NCBI chr 4:95,498,003...95,500,098
Ensembl chr 4:95,498,003...95,500,089

G

ATPase plasma membrane Ca2+ transporting 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP2B2 mRNA

NCBI chr 4:145,704,779...145,948,997
Ensembl chr 4:145,703,046...146,016,325

G

ATPase plasma membrane Ca2+ transporting 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP2B3 mRNA

NCBI chr X:157,236,400...157,312,028
Ensembl chr X:157,239,306...157,312,028

G

ATPase plasma membrane Ca2+ transporting 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP2B4 mRNA

NCBI chr13:50,091,644...50,153,808
Ensembl chr13:50,091,430...50,153,823

G

ATP synthase F1 subunit epsilon

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP5E mRNA

NCBI chr 3:172,563,105...172,566,007
Ensembl chr 3:172,563,105...172,566,010

G

ATP synthase membrane subunit c locus 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP5G1 mRNA

NCBI chr10:83,895,941...83,898,640
Ensembl chr10:83,895,947...83,898,527

G

ATP synthase membrane subunit f

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP5J2 mRNA

NCBI chr12:11,191,799...11,198,369
Ensembl chr12:11,191,812...11,198,369

G

ATP synthase membrane subunit g

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP5L mRNA

NCBI chr 8:49,220,441...49,227,273
Ensembl chr 8:49,220,443...49,227,273

G

ATP synthase membrane subunit k

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP5MD mRNA

NCBI chr 1:266,859,961...266,866,753
Ensembl chr 1:266,862,579...266,862,842

G

ATP synthase peripheral stalk subunit d

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of ATP5H mRNA

NCBI chr10:103,967,340...103,972,552
Ensembl chr10:103,967,312...103,972,668

G

ATPase H+ transporting accessory protein 1 like

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP6AP1L mRNA

NCBI chr 2:19,781,375...19,809,355
Ensembl chr 2:19,781,408...19,808,937

G

ATPase H+ transporting V1 subunit G3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP6V1G3 mRNA

NCBI chr13:55,265,794...55,288,651
Ensembl chr13:55,274,199...55,288,651

G

ATR serine/threonine kinase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ATR mRNA

NCBI chr 8:103,673,578...103,770,886
Ensembl chr 8:103,673,411...103,770,947

G

ataxin 7-like 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ATXN7L2 mRNA

NCBI chr 2:210,992,904...211,001,287
Ensembl chr 2:210,992,953...211,001,258

G

AU RNA binding methylglutaconyl-CoA hydratase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AUH mRNA

NCBI chr17:12,310,178...12,405,224
Ensembl chr17:12,310,214...12,405,205

G

aurora kinase A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AURKA mRNA

NCBI chr 3:170,364,177...170,380,278
Ensembl chr 3:170,364,181...170,378,210

G

aurora kinase B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AURKB mRNA

NCBI chr10:55,625,860...55,632,399
Ensembl chr10:55,626,741...55,634,991

G

arginine vasopressin-induced 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AVPI1 mRNA

NCBI chr 1:261,365,590...261,371,519
Ensembl chr 1:261,365,590...261,371,508

G

alpha-2-glycoprotein 1, zinc-binding

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AZGP1 mRNA

NCBI chr12:19,196,565...19,203,094
Ensembl chr12:19,196,611...19,202,647

G

beta-1,3-glucuronyltransferase 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of B3GAT1 mRNA

NCBI chr 8:27,777,024...27,804,368
Ensembl chr 8:27,777,179...27,804,515

G

beta-1,3-glucuronyltransferase 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of B3GAT2 mRNA

NCBI chr 9:29,984,077...30,068,649
Ensembl chr 9:29,984,077...30,068,649

G

beta-1,4-N-acetyl-galactosaminyl transferase 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of B4GALNT4 mRNA

NCBI chr 1:213,870,328...213,881,233
Ensembl chr 1:213,870,502...213,881,917

G

BRISC and BRCA1 A complex member 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BABAM2 mRNA

NCBI chr 6:25,666,654...26,135,888
Ensembl chr 6:25,666,655...26,051,229

G

BRCA1 associated RING domain 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BARD1 mRNA

NCBI chr 9:78,297,723...78,368,777
Ensembl chr 9:78,294,834...78,369,031

G

BarH-like homeobox 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BARHL1 mRNA

NCBI chr 3:7,491,234...7,498,555
Ensembl chr 3:7,491,234...7,498,555

G

BARX homeobox 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BARX2 mRNA

NCBI chr 8:32,950,878...33,018,245
Ensembl chr 8:32,950,875...33,017,854

G

bromodomain adjacent to zinc finger domain, 1A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BAZ1A mRNA

NCBI chr 6:75,793,223...75,873,854
Ensembl chr 6:75,793,960...75,874,235

G

bromodomain adjacent to zinc finger domain, 2B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BAZ2B mRNA

NCBI chr 3:45,968,845...46,286,915
Ensembl chr 3:45,968,825...46,153,371

G

Bardet-Biedl syndrome 4

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of BBS4 mRNA

NCBI chr 8:64,115,005...64,154,432
Ensembl chr 8:64,121,392...64,154,396

G

BBX high mobility group box domain containing

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BBX mRNA

NCBI chr11:52,983,286...53,228,557
Ensembl chr11:53,081,025...53,228,716

G

BCL2 like 14

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BCL2L14 mRNA

NCBI chr 4:168,139,964...168,183,726
Ensembl chr 4:168,142,271...168,183,096

G

beclin 1

increases expression
multiple interactions

2,5,2',5'-tetrachlorobiphenyl results in increased expression of BECN1 protein
3-methyladenine inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of BECN1 protein]

NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297

G

BEN domain containing 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BEND4 mRNA

NCBI chr14:42,399,359...42,401,643
NCBI chr14:42,401,665...42,437,957
Ensembl chr14:42,401,706...42,431,480

G

BEN domain containing 7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BEND7 mRNA

NCBI chr17:77,448,430...77,527,888
Ensembl chr17:77,448,430...77,527,894

G

bone gamma-carboxyglutamate protein

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of BGLAP mRNA

NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747

G

baculoviral IAP repeat-containing 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BIRC3 mRNA

NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598

G

baculoviral IAP repeat-containing 5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BIRC5 mRNA

NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413

G

BCL2 interacting protein 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BNIP2 mRNA

NCBI chr 8:76,400,333...76,426,307
Ensembl chr 8:76,400,341...76,426,503

G

biorientation of chromosomes in cell division 1-like 1

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of BOD1L mRNA

NCBI chr14:73,738,137...73,792,935
Ensembl chr14:73,738,137...73,791,656

G

bora, aurora kinase A activator

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BORA mRNA

NCBI chr15:83,442,217...83,463,737
Ensembl chr15:83,442,144...83,463,717

G

bactericidal/permeability-increasing protein

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of BPI mRNA

NCBI chr 3:154,741,627...154,768,584
Ensembl chr 3:154,741,631...154,768,640

G

BPI fold containing family B, member 6

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BPIFB6 mRNA

NCBI chr 3:149,382,312...149,396,130
Ensembl chr 3:149,391,929...149,396,130

G

BRCA2, DNA repair associated

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRCA2 mRNA; [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRCA2 protein

NCBI chr12:503,660...544,754
Ensembl chr12:504,007...544,748

G

bromodomain containing 8

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRD8 mRNA

NCBI chr18:27,375,645...27,423,989
Ensembl chr18:27,398,688...27,424,090

G

BRICHOS domain containing 5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BRICD5 mRNA

NCBI chr10:13,839,599...13,841,132
Ensembl chr10:13,839,956...13,841,018

G

BMP/retinoic acid inducible neural specific 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BRINP3 mRNA

NCBI chr13:63,526,486...63,959,390
Ensembl chr13:63,526,486...63,959,332

G

BRCA1 interacting protein C-terminal helicase 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRIP1 mRNA

NCBI chr10:73,507,009...73,632,742
Ensembl chr10:73,507,100...73,629,581

G

bromodomain and WD repeat domain containing 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BRWD3 mRNA

NCBI chr X:79,817,968...79,909,891
Ensembl chr X:79,824,782...79,909,678

G

BTG anti-proliferation factor 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BTG1 mRNA

NCBI chr 7:37,812,831...37,815,088
Ensembl chr 7:37,812,831...37,815,088

G

BUB1 mitotic checkpoint serine/threonine kinase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BUB1 mRNA

NCBI chr 3:120,373,604...120,404,910
Ensembl chr 3:120,373,604...120,404,910

G

BUB1 mitotic checkpoint serine/threonine kinase B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BUB1B mRNA

NCBI chr 3:110,367,949...110,420,471
Ensembl chr 3:110,367,939...110,420,458

G

blood vessel epicardial substance

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BVES mRNA

NCBI chr20:50,439,885...50,474,678
Ensembl chr20:50,439,883...50,474,678

G

complement C1q like 2

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of C1QL2 mRNA

NCBI chr13:36,378,187...36,379,722
Ensembl chr13:36,378,356...36,380,302

G

C1q and TNF related 4

increases expression
multiple interactions

2,5,2',5'-tetrachlorobiphenyl results in increased expression of C1QTNF4 mRNA
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of C1QTNF4 mRNA

PMID:23829299 PMID:25510870

NCBI chr 3:79,713,580...79,718,018
Ensembl chr 3:79,713,567...79,718,025

G

complement C7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of C7 mRNA

NCBI chr 2:54,707,621...54,781,624
Ensembl chr 2:54,709,138...54,777,729

G

complement C8 beta chain

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of C8B mRNA

NCBI chr 5:124,298,269...124,338,055
Ensembl chr 5:124,300,477...124,338,053

G

carbonic anhydrase 12

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAR12 mRNA

NCBI chr 8:72,405,770...72,461,425
Ensembl chr 8:72,405,748...72,460,240

G

carbonic anhydrase 8

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAR8 mRNA

NCBI chr 5:21,249,018...21,345,810
Ensembl chr 5:21,249,020...21,345,810

G

calcium voltage-gated channel subunit alpha1 F

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CACNA1F mRNA

NCBI chr X:15,712,709...15,741,135
Ensembl chr X:15,712,713...15,741,103

G

calcium voltage-gated channel auxiliary subunit gamma 7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CACNG7 mRNA

NCBI chr 1:64,374,547...64,405,380
Ensembl chr 1:64,374,603...64,405,149

G

calbindin 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CALB1 mRNA

NCBI chr 5:29,538,380...29,562,774
Ensembl chr 5:29,538,380...29,562,773

G

calbindin 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CALB2 mRNA

NCBI chr19:41,482,743...41,509,617
Ensembl chr19:41,482,728...41,509,658

G

calmodulin 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CALM3 mRNA

NCBI chr 1:78,844,520...78,851,628
Ensembl chr 1:78,843,080...78,851,719

G

calcyon neuron-specific vesicular protein

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CALY mRNA

NCBI chr 1:212,537,851...212,549,040
Ensembl chr 1:212,537,848...212,549,477

G

calcium/calmodulin-dependent protein kinase II alpha

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAMK2A mRNA

NCBI chr18:56,193,978...56,295,869
Ensembl chr18:56,193,978...56,295,869

G

calcium/calmodulin-dependent protein kinase II beta

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAMK2B mRNA

NCBI chr14:86,208,876...86,297,727
Ensembl chr14:86,208,901...86,297,652

G

calcium/calmodulin-dependent protein kinase II inhibitor 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAMK2N1 mRNA

NCBI chr 5:156,876,706...156,878,486
Ensembl chr 5:156,876,706...156,878,486

G

calcium/calmodulin-dependent protein kinase IV

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAMK4 mRNA

NCBI chr18:25,746,878...25,975,962
Ensembl chr18:25,749,098...25,965,957

G

calcium/calmodulin-dependent protein kinase kinase 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAMKK2 mRNA

NCBI chr12:39,253,409...39,302,601
Ensembl chr12:39,253,409...39,302,601

G

cyclase associated actin cytoskeleton regulatory protein 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAP2 mRNA

NCBI chr17:18,441,614...18,592,866
Ensembl chr17:18,442,127...18,592,750

G

capping actin protein of muscle Z-line subunit alpha 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CAPZA1 mRNA

NCBI chr 2:207,305,748...207,350,812
Ensembl chr 2:207,305,752...207,350,812

G

carbonic anhydrase 7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAR7 mRNA

NCBI chr19:636,545...645,935
Ensembl chr19:636,545...645,937

G

CART prepropeptide

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CARTPT mRNA

NCBI chr 2:30,125,249...30,127,408
Ensembl chr 2:30,125,249...30,127,269

G

castor zinc finger 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CASZ1 mRNA

NCBI chr 5:165,625,119...165,777,053
Ensembl chr 5:165,724,027...165,774,616

G

cation channel sperm associated auxiliary subunit delta

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CATSPERD mRNA

NCBI chr 9:10,390,307...10,428,666
Ensembl chr 9:10,390,308...10,427,746

G

cation channel sperm associated auxiliary subunit gamma

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CATSPERG1 mRNA

NCBI chr 1:88,131,282...88,162,609
Ensembl chr 1:88,131,554...88,162,583

G

cerebellin 4 precursor

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CBLN4 mRNA

NCBI chr 3:170,033,166...170,040,953
Ensembl chr 3:170,033,166...170,040,953

G

chromobox 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CBX2 mRNA

NCBI chr10:108,132,105...108,140,935
Ensembl chr10:108,132,105...108,140,935

G

chromobox 7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CBX7 mRNA

NCBI chr 7:121,136,067...121,153,503
Ensembl chr 7:121,136,058...121,153,383

G

chibby family member 2

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CBY2 mRNA

NCBI chr15:57,642,576...57,738,383
Ensembl chr15:57,642,577...57,651,041

G

coiled-coil domain containing 116

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCDC116 mRNA

NCBI chr11:88,092,794...88,100,220
Ensembl chr11:88,095,170...88,098,252

G

coiled-coil domain containing 148

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCDC148 mRNA

NCBI chr 3:44,892,212...45,210,897
Ensembl chr 3:44,892,219...45,210,474

G

coiled-coil domain containing 175

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCDC175 mRNA

NCBI chr 6:94,849,910...94,933,175
Ensembl chr 6:94,849,989...94,932,806

G

coiled-coil domain containing 179

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CCDC179 mRNA

NCBI chr 1:107,381,355...107,385,257
Ensembl chr 1:107,381,357...107,385,257

G

coiled-coil domain containing 60

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCDC60 mRNA

NCBI chr12:46,042,422...46,206,748
Ensembl chr12:46,042,413...46,206,747

G

coiled-coil domain containing 70

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCDC70 mRNA

NCBI chr16:74,958,897...74,963,925
Ensembl chr16:74,958,897...74,963,044

G

coiled-coil domain containing 74A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCDC74A mRNA

NCBI chr11:87,547,026...87,554,513
Ensembl chr11:87,549,059...87,553,336

G

coiled-coil domain containing 8

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCDC8 mRNA

NCBI chr 1:78,933,372...78,936,700
Ensembl chr 1:78,933,372...78,936,700

G

coiled-coil domain containing 83

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCDC83 mRNA

NCBI chr 1:154,478,426...154,507,075
NCBI chr 1:156,485,039...156,509,513
Ensembl chr 1:154,478,782...154,507,039

G

coiled-coil domain containing 85B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCDC85B mRNA

NCBI chr 1:220,835,647...220,837,220

G

coiled-coil domain containing 85C

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCDC85C mRNA

NCBI chr 6:132,113,806...132,183,434

G

cholecystokinin

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCK mRNA

NCBI chr 8:130,120,525...130,127,515
Ensembl chr 8:130,120,523...130,127,392

G

C-C motif chemokine ligand 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCL1 mRNA

NCBI chr10:69,534,976...69,537,836
Ensembl chr10:69,534,933...69,537,882

G

C-C motif chemokine ligand 19

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CCL19 mRNA

NCBI chr 5:58,181,025...58,182,969
Ensembl chr 5:58,181,026...58,183,017

G

C-C motif chemokine ligand 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCL2 mRNA

NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870

G

C-C motif chemokine ligand 28

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCL28 mRNA

NCBI chr 2:52,379,341...52,403,979
Ensembl chr 2:52,379,341...52,404,246

G

cyclin A1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCNA1 mRNA

NCBI chr 2:144,456,689...144,503,570
Ensembl chr 2:144,458,153...144,467,912

G

cyclin A2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCNA2 mRNA

NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214

G

cyclin B1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCNB1 mRNA

NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221

G

cyclin B2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCNB2 mRNA

NCBI chr 8:76,847,972...76,861,165

G

cyclin D2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCND2 mRNA

NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207

G

cyclin E1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCNE1 mRNA

NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980

G

cyclin F

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCNF mRNA

NCBI chr10:13,594,687...13,619,935
Ensembl chr10:13,594,687...13,619,935

G

CD1d1 molecule

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CD1D1 mRNA

NCBI chr 2:186,330,298...186,333,805
Ensembl chr 2:186,330,298...186,333,805

G

Cd276 molecule

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CD276 mRNA

NCBI chr 8:63,312,060...63,350,411
Ensembl chr 8:63,318,019...63,350,269

G

Cd300 molecule-like family member D

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CD300LD mRNA

NCBI chr10:104,847,315...104,895,630

G

CD320 molecule

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CD320 mRNA

NCBI chr 7:18,700,445...18,706,244
Ensembl chr 7:18,700,344...18,706,244

G

Cd6 molecule

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CD6 mRNA

NCBI chr 1:226,848,399...226,887,259
Ensembl chr 1:226,848,403...226,887,156

G

Cd70 molecule

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CD70 mRNA

NCBI chr 9:9,842,585...9,845,728
Ensembl chr 9:9,842,585...9,845,728

G

Cd80 molecule

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CD80 mRNA

NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353

G

CD8a molecule

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CD8A mRNA

NCBI chr 4:99,217,640...99,243,352
Ensembl chr 4:99,239,115...99,243,351

G

CD93 molecule

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CD93 mRNA

NCBI chr 3:142,778,798...142,783,774
Ensembl chr 3:142,778,770...142,783,774

G

CD96 molecule

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CD96 mRNA

NCBI chr11:57,108,757...57,183,855
Ensembl chr11:57,108,956...57,183,270

G

cell division cycle 20

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDC20 mRNA

NCBI chr 5:137,260,728...137,264,931
Ensembl chr 5:137,260,739...137,265,015

G

cell division cycle 25B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDC25B mRNA

NCBI chr 3:123,731,539...123,741,696
Ensembl chr 3:123,731,539...123,741,339

G

cell division cycle 25C

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDC25C mRNA

NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224

G

CDC42 binding protein kinase alpha

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CDC42BPA mRNA

NCBI chr13:98,231,326...98,447,762
Ensembl chr13:98,231,326...98,447,762

G

cell division cycle 6

decreases expression
multiple interactions

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of CDC6 mRNA
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDC6 mRNA

PMID:23829299 PMID:25510870

NCBI chr10:86,819,477...86,833,301
Ensembl chr10:86,819,472...86,833,402

G

cell division cycle associated 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDCA2 mRNA

NCBI chr15:44,365,396...44,411,601
Ensembl chr15:44,365,405...44,411,004

G

cell division cycle associated 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDCA3 mRNA

NCBI chr 4:157,347,876...157,351,889
Ensembl chr 4:157,348,020...157,351,604

G

cell division cycle associated 5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDCA5 mRNA

NCBI chr 1:221,448,661...221,462,235
Ensembl chr 1:221,448,661...221,462,233

G

cell division cycle associated 7 like

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDCA7L mRNA

NCBI chr 6:145,739,570...145,785,607
Ensembl chr 6:145,740,035...145,785,606

G

cell division cycle associated 8

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDCA8 mRNA

NCBI chr 5:142,911,310...142,933,536
Ensembl chr 5:142,911,305...142,933,526

G

cadherin 18

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CDH18 mRNA

NCBI chr 2:73,651,408...74,693,342
Ensembl chr 2:74,360,622...74,693,341

G

cadherin 22

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CDH22 mRNA

NCBI chr 3:161,574,993...161,971,102
Ensembl chr 3:161,575,631...161,917,285

G

cadherin-related 23

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CDH23 mRNA

NCBI chr20:29,857,018...30,263,758
Ensembl chr20:29,857,637...29,990,111

G

cadherin 5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDH5 mRNA

NCBI chr19:1,025,122...1,074,333
Ensembl chr19:1,023,683...1,074,365

G

cadherin 7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CDH7 mRNA

NCBI chr13:31,081,064...31,228,884
Ensembl chr13:31,081,804...31,231,213

G

cadherin 8

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CDH8 mRNA

NCBI chr19:6,031,654...6,431,502
Ensembl chr19:6,046,665...6,426,216

G

cyclin-dependent kinase 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDK1 mRNA

NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549

G

cyclin dependent kinase 2

increases expression
multiple interactions

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CDK2 mRNA
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDK2 mRNA

PMID:21703328 PMID:25510870

NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457

G

cyclin-dependent kinase 6

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDK6 mRNA

NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398

G

cell adhesion associated, oncogene regulated

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CDON mRNA

NCBI chr 8:36,625,757...36,712,091
Ensembl chr 8:36,625,733...36,710,949

G

chromatin licensing and DNA replication factor 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDT1 mRNA

NCBI chr19:55,381,565...55,386,511
Ensembl chr19:55,381,565...55,386,511

G

CEA cell adhesion molecule 12

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CEACAM11 mRNA

NCBI chr 1:79,474,809...79,481,865
Ensembl chr 1:79,474,809...79,481,865

G

CECR2, histone acetyl-lysine reader

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CECR2 mRNA

NCBI chr 4:153,217,521...153,327,153
Ensembl chr 4:153,217,782...153,322,564

G

chymotrypsin like elastase 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CELA1 mRNA

NCBI chr 7:142,305,337...142,318,621
Ensembl chr 7:142,305,338...142,318,620

G

CUGBP, Elav-like family member 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CELF1 mRNA

NCBI chr 3:79,768,900...79,844,548
Ensembl chr 3:79,823,945...79,842,082

G

cadherin, EGF LAG seven-pass G-type receptor 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CELSR2 mRNA

NCBI chr 2:211,183,410...211,207,458
Ensembl chr 2:211,183,311...211,207,465

G

cadherin, EGF LAG seven-pass G-type receptor 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CELSR3 mRNA

NCBI chr 8:117,620,293...117,648,034
Ensembl chr 8:117,620,317...117,648,028

G

cell migration inducing hyaluronidase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CEMIP mRNA

NCBI chr 1:146,069,774...146,226,320
Ensembl chr 1:146,069,771...146,226,462

G

centromere protein E

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPE mRNA

NCBI chr 2:240,395,974...240,454,785
Ensembl chr 2:240,396,152...240,454,747

G

centromere protein F

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPF mRNA

NCBI chr13:108,132,499...108,178,609
Ensembl chr13:108,132,499...108,178,609

G

centromere protein H

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPH mRNA

NCBI chr 2:30,766,637...30,780,123
Ensembl chr 2:30,766,590...30,780,121

G

centromere protein I

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPI mRNA

NCBI chr X:105,147,045...105,198,798
Ensembl chr X:105,147,153...105,198,797

G

centromere protein J

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPJ mRNA

NCBI chr15:36,745,672...36,809,228
Ensembl chr15:36,746,088...36,798,814

G

centromere protein K

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPK mRNA

NCBI chr 2:34,312,766...34,373,945
Ensembl chr 2:34,312,766...34,335,776

G

centromere protein M

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPM mRNA

NCBI chr 7:123,464,615...123,476,336
Ensembl chr 7:123,464,490...123,476,238

G

centromere protein N

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPN mRNA

NCBI chr19:49,457,461...49,479,989
Ensembl chr19:49,340,184...49,479,996

G

centromere protein P

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPP mRNA

NCBI chr17:15,429,526...15,603,197
Ensembl chr17:15,429,708...15,603,199

G

centromere protein S

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CENPS mRNA

NCBI chr 5:165,946,106...165,955,723

G

centromere protein T

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CENPT mRNA

NCBI chr19:37,813,284...37,819,782
Ensembl chr19:37,812,751...37,819,789

G

centromere protein U

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPU mRNA

NCBI chr16:48,898,032...48,921,248
Ensembl chr16:48,897,982...48,921,242

G

centrosomal protein 164

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CEP164 mRNA

NCBI chr 8:50,069,282...50,132,477
Ensembl chr 8:50,070,579...50,126,413

G

centrosomal protein 295

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CEP295 mRNA

NCBI chr 8:13,871,065...13,909,249
Ensembl chr 8:13,871,213...13,909,188

G

centrosomal protein 55

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CEP55 mRNA

NCBI chr 1:256,745,251...256,760,794
Ensembl chr 1:256,745,288...256,760,796

G

ceramide synthase 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CERS3 mRNA

NCBI chr 1:127,706,618...127,781,041
Ensembl chr 1:127,648,234...127,781,017

G

cilia and flagella associated protein 100

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CFAP100 mRNA

NCBI chr 4:122,314,462...122,338,862
Ensembl chr 4:122,314,458...122,337,389

G

chromatin assembly factor 1 subunit A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CHAF1A mRNA

NCBI chr 9:11,000,869...11,027,631
Ensembl chr 9:11,001,129...11,027,506

G

chromatin assembly factor 1 subunit B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CHAF1B mRNA

NCBI chr11:34,101,248...34,121,371
Ensembl chr11:34,101,197...34,121,378

G

charged multivesicular body protein 4C

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CHMP4C mRNA

NCBI chr 2:93,574,554...93,641,497
Ensembl chr 2:93,574,559...93,641,497

G

chimerin 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CHN2 mRNA

NCBI chr 4:84,423,708...84,452,989
Ensembl chr 4:84,194,347...84,454,500

G

cholinergic receptor, muscarinic 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CHRM1 mRNA

NCBI chr 1:224,869,087...224,885,101
Ensembl chr 1:224,882,439...224,884,205

G

cholinergic receptor nicotinic alpha 10 subunit

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CHRNA10 mRNA

NCBI chr 1:167,206,722...167,212,199
Ensembl chr 1:167,206,722...167,210,919

G

cholinergic receptor nicotinic alpha 3 subunit

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CHRNA3 mRNA

NCBI chr 8:59,594,007...59,607,122
Ensembl chr 8:59,592,403...59,607,275

G

carbohydrate sulfotransferase 15

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CHST15 mRNA

NCBI chr 1:204,243,396...204,328,960
Ensembl chr 1:204,245,645...204,322,544

G

churchill domain containing 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CHURC1 mRNA

NCBI chr 6:99,817,439...99,831,574
Ensembl chr 6:99,817,431...99,831,576

G

calcium and integrin binding family member 2

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CIB2 mRNA

NCBI chr 8:59,123,078...59,139,946
Ensembl chr 8:59,123,079...59,139,946

G

CBY1 interacting BAR domain containing 1

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CIBAR1 mRNA

NCBI chr 5:25,732,457...25,750,953
Ensembl chr 5:25,732,644...25,750,826

G

cartilage intermediate layer protein

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CILP mRNA

NCBI chr 8:70,760,922...70,775,891
Ensembl chr 8:70,760,922...70,775,891

G

cytokine inducible SH2-containing protein

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CISH mRNA

NCBI chr 8:116,054,547...116,059,494
Ensembl chr 8:116,054,465...116,060,723

G

cytoskeleton associated protein 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CKAP2 mRNA

NCBI chr16:74,752,655...74,779,184
Ensembl chr16:74,752,655...74,779,184

G

cytoskeleton associated protein 2-like

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CKAP2L mRNA

NCBI chr 3:121,796,221...121,822,352
Ensembl chr 3:121,796,238...121,822,436

G

cytoskeleton-associated protein 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CKAP4 mRNA

NCBI chr 7:24,935,243...24,947,595
Ensembl chr 7:24,939,498...24,947,595

G

cytoskeleton associated protein 5

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CKAP5 mRNA

NCBI chr 3:80,424,320...80,526,583
Ensembl chr 3:80,468,154...80,526,593

G

chemokine-like factor

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CKLF mRNA

NCBI chr19:903,609...914,880
Ensembl chr19:906,411...914,880

G

CDC28 protein kinase regulatory subunit 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CKS2 mRNA

NCBI chr17:13,587,664...13,593,423
Ensembl chr17:13,587,665...13,593,423

G

claudin 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CLDN2 mRNA

NCBI chr X:111,122,552...111,133,188
Ensembl chr X:111,122,552...111,137,769

G

claudin 3

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CLDN3 mRNA

NCBI chr12:21,831,341...21,832,813
Ensembl chr12:21,831,342...21,832,813

G

claudin 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CLDN4 mRNA

NCBI chr12:24,761,210...24,763,008
Ensembl chr12:24,761,210...24,763,005

G

C-type lectin domain family 12, member B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CLEC12B mRNA

NCBI chr 4:163,140,883...163,157,996
Ensembl chr 4:163,141,132...163,157,744

G

C-type lectin domain containing 5A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CLEC5A mRNA

NCBI chr 4:68,810,330...68,819,921
Ensembl chr 4:68,808,359...68,819,928

G

C-type lectin domain containing 7A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CLEC7A mRNA

NCBI chr 4:163,216,152...163,227,367
Ensembl chr 4:163,216,163...163,227,334

G

clathrin heavy chain linker domain containing 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CLHC1 mRNA

NCBI chr14:113,968,563...114,008,015
Ensembl chr14:113,968,563...114,008,000

G

CXADR-like membrane protein

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CLMP mRNA

NCBI chr 8:44,846,685...44,975,460
Ensembl chr 8:44,847,157...44,975,457

G

clock circadian regulator

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CLOCK mRNA

NCBI chr14:34,418,226...34,502,218
Ensembl chr14:34,446,616...34,502,218

G

clarin 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CLRN2 mRNA

NCBI chr14:70,150,983...70,160,624
Ensembl chr14:70,150,983...70,160,624

G

clarin 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CLRN3 mRNA

NCBI chr 1:207,750,627...207,766,250
Ensembl chr 1:207,750,223...207,811,008

G

claspin

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CLSPN mRNA

NCBI chr 5:144,577,670...144,617,507
Ensembl chr 5:144,581,427...144,616,335

G

calsyntenin 3

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CLSTN3 mRNA

NCBI chr 4:157,044,736...157,078,013
Ensembl chr 4:157,043,925...157,078,130

G

chymase 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CMA1 mRNA

NCBI chr15:34,601,037...34,603,819
Ensembl chr15:34,601,037...34,603,819

G

cytidine/uridine monophosphate kinase 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CMPK2 mRNA

NCBI chr 6:45,683,242...45,694,824
Ensembl chr 6:45,683,234...45,694,822

G

cornichon family AMPA receptor auxiliary protein 2

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CNIH2 mRNA

NCBI chr 1:220,474,485...220,480,723
Ensembl chr 1:220,474,493...220,480,132

G

cyclin and CBS domain divalent metal cation transport mediator 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CNNM3 mRNA

NCBI chr 9:43,093,120...43,108,486
Ensembl chr 9:43,093,138...43,108,486

G

canopy FGF signaling regulator 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CNPY1 mRNA

NCBI chr 4:474,424...496,826
Ensembl chr 4:476,977...482,645

G

centlein

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CNTLN mRNA

NCBI chr 5:103,251,986...103,367,088
Ensembl chr 5:103,251,986...103,366,264

G

contactin 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CNTN2 mRNA

NCBI chr13:49,280,913...49,314,061
Ensembl chr13:49,285,310...49,313,940

G

contactin 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CNTN4 mRNA

NCBI chr 4:137,785,166...138,787,527
Ensembl chr 4:138,269,142...138,787,525

G

contactin associated protein 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CNTNAP2 mRNA

NCBI chr 4:74,700,539...77,025,463

G

centriolin

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CNTRL mRNA

NCBI chr 3:14,299,441...14,371,681
Ensembl chr 3:14,299,479...14,371,681

G

centrobin, centriole duplication and spindle assembly protein

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CNTROB mRNA

NCBI chr10:55,901,929...55,927,121
Ensembl chr10:55,901,901...55,924,158

G

cytochrome C oxidase assembly factor 5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COA5 mRNA

NCBI chr 9:44,011,471...44,024,876
Ensembl chr 9:44,011,471...44,024,876

G

cochlin

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COCH mRNA

NCBI chr 6:72,359,702...72,373,710
Ensembl chr 6:72,359,791...72,373,695

G

component of oligomeric golgi complex 5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of COG5 mRNA

NCBI chr 6:50,953,868...51,230,860
Ensembl chr 6:50,954,631...51,230,701

G

component of oligomeric golgi complex 7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of COG7 mRNA

NCBI chr 1:191,889,332...191,948,977
Ensembl chr 1:191,857,556...191,948,977

G

collagen type XI alpha 1 chain

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of COL11A1 mRNA

NCBI chr 2:216,863,423...217,056,523
Ensembl chr 2:216,863,428...217,056,523

G

collagen type XII alpha 1 chain

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COL12A1 mRNA

NCBI chr 8:87,042,820...87,150,701
Ensembl chr 8:87,040,799...87,158,368

G

collagen type XVIII alpha 1 chain

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of COL18A1 mRNA

NCBI chr20:12,225,202...12,332,858
Ensembl chr20:12,225,202...12,332,858

G

collagen type XXIV alpha 1 chain

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COL24A1 mRNA

NCBI chr 2:251,200,686...251,436,254
Ensembl chr 2:251,200,686...251,434,932

G

collagen type IV alpha 1 chain

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of COL4A1 mRNA

NCBI chr16:83,522,162...83,632,153
Ensembl chr16:83,522,162...83,632,153

G

collagen type IV alpha 3 chain

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of COL4A3 mRNA

NCBI chr 9:88,357,528...88,484,735
Ensembl chr 9:88,357,556...88,485,830

G

collagen type VI alpha 3 chain

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of COL6A3 mRNA

NCBI chr 9:97,926,784...98,004,643
Ensembl chr 9:97,926,787...98,004,546

G

COP9 signalosome subunit 9

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COPS9 mRNA

NCBI chr 9:99,813,332...99,818,262
Ensembl chr 9:99,813,332...99,818,262

G

COPI coat complex subunit zeta 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COPZ2 mRNA

NCBI chr10:84,718,824...84,731,880
Ensembl chr10:84,718,824...84,731,880

G

coronin 2A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CORO2A mRNA

NCBI chr 5:62,154,526...62,210,797
Ensembl chr 5:62,156,839...62,187,930

G

cortistatin

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CORT mRNA

NCBI chr 5:165,942,780...165,944,221

G

cytochrome c oxidase subunit 4i1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COX4I1 mRNA

NCBI chr19:54,245,958...54,252,198
Ensembl chr19:54,245,950...54,252,225

G

cytochrome c oxidase subunit 6B2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COX6B2 mRNA

NCBI chr 1:72,661,099...72,662,436
Ensembl chr 1:72,661,211...72,662,434

G

cytochrome c oxidase subunit 7A1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COX7A1 mRNA

NCBI chr 1:88,619,619...88,650,672
Ensembl chr 1:91,071,493...91,074,294
Ensembl chr 1:91,071,493...91,074,294

G

carboxypeptidase A2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CPA2 mRNA

NCBI chr 4:57,855,416...57,879,239
Ensembl chr 4:57,855,416...57,879,239

G

carboxypeptidase E

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of CPE mRNA

NCBI chr16:26,906,716...27,014,811
Ensembl chr16:26,906,716...27,014,813

G

complexin 1

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CPLX1 mRNA

NCBI chr14:2,194,895...2,226,610
Ensembl chr14:2,194,933...2,226,598

G

copine 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CPNE1 mRNA

NCBI chr 3:151,617,733...151,625,448
NCBI chr 3:152,150,143...152,192,936
Ensembl chr 3:151,616,037...151,625,644
Ensembl chr 3:151,616,037...151,625,644

G

copine family member 9

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CPNE9 mRNA

NCBI chr 4:145,238,011...145,262,444
Ensembl chr 4:145,238,947...145,262,442

G

cleavage and polyadenylation specific factor 4-like

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CPSF4L mRNA

NCBI chr10:102,213,892...102,227,708

G

ceramide-1-phosphate transfer protein

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CPTP mRNA

NCBI chr 5:173,314,219...173,318,384
Ensembl chr 5:173,314,228...173,318,313

G

CRACD like

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CRACDL mRNA

NCBI chr 9:44,194,348...44,309,816
Ensembl chr 9:44,194,325...44,237,117

G

crumbs cell polarity complex component 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CRB3 mRNA

NCBI chr 9:9,982,529...9,986,896
Ensembl chr 9:9,980,720...9,985,630

G

cAMP responsive element binding protein-like 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CREBL2 mRNA

NCBI chr 4:168,599,387...168,625,239
Ensembl chr 4:168,599,331...168,619,764

G

corticotropin releasing hormone receptor 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CRHR2 mRNA

NCBI chr 4:85,286,371...85,329,374
Ensembl chr 4:85,286,372...85,329,362

G

cysteine-rich secretory protein 2

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CRISP2 mRNA

NCBI chr 9:23,503,223...23,527,502
Ensembl chr 9:23,503,236...23,527,496

G

cytokine receptor-like factor 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CRLF1 mRNA

NCBI chr16:20,675,042...20,686,365
Ensembl chr16:20,675,042...20,686,317

G

cytotoxic and regulatory T cell molecule

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CRTAM mRNA

NCBI chr 8:45,152,584...45,216,082
Ensembl chr 8:45,153,308...45,215,974

G

crystallin, alpha B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CRYAB mRNA

NCBI chr 8:55,178,543...55,182,546
Ensembl chr 8:55,178,289...55,182,545

G

crystallin, beta B2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CRYBB2 mRNA

NCBI chr12:49,577,580...49,588,555
Ensembl chr12:49,578,633...49,588,555

G

crystallin beta-gamma domain containing 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CRYBG3 mRNA

NCBI chr11:42,895,610...43,006,568
Ensembl chr11:42,945,084...43,005,097

G

cold shock domain containing C2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CSDC2 mRNA

NCBI chr 7:123,168,811...123,183,336
Ensembl chr 7:123,168,811...123,183,335

G

CUB and Sushi multiple domains 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CSMD3 mRNA

NCBI chr 7:86,695,703...88,072,106
Ensembl chr 7:86,673,993...88,071,472

G

casein kappa

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CSN3 mRNA

NCBI chr14:21,803,738...21,810,291
Ensembl chr14:21,803,735...21,810,314

G

centrosome and spindle pole associated protein 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CSPP1 mRNA

NCBI chr 5:8,761,293...8,876,205
Ensembl chr 5:8,761,293...8,864,578

G

cysteine and glycine-rich protein 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CSRP1 mRNA

NCBI chr13:52,553,843...52,575,054
Ensembl chr13:52,553,775...52,575,051

G

cystatin C

decreases expression
multiple interactions

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of CST3 mRNA
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CST3 mRNA

PMID:23829299 PMID:25510870

NCBI chr 3:143,219,671...143,223,544
Ensembl chr 3:143,219,686...143,223,615

G

cystatin E/M

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CST6 mRNA

NCBI chr 1:220,727,292...220,729,000
Ensembl chr 1:220,727,292...220,729,000

G

CTD small phosphatase like

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CTDSPL mRNA

NCBI chr 8:127,065,292...127,726,248
Ensembl chr 8:127,702,534...127,726,127

G

catenin delta 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CTNND1 mRNA

NCBI chr 3:72,001,904...72,053,047
Ensembl chr 3:72,002,152...72,053,049

G

cystinosin, lysosomal cystine transporter

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CTNS mRNA

NCBI chr10:59,749,250...59,772,475
Ensembl chr10:59,749,256...59,764,868

G

chymotrypsin C

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CTRC mRNA

NCBI chr 5:160,394,677...160,403,373
Ensembl chr 5:160,394,580...160,405,050

G

cortexin 1

decreases expression
multiple interactions

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of CTXN1 mRNA
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CTXN1 mRNA

PMID:23829299 PMID:25510870

NCBI chr12:2,534,212...2,535,823
Ensembl chr12:2,534,212...2,535,822

G

C-X-C motif chemokine ligand 12

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CXCL12 mRNA

NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891

G

cytochrome c, testis

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CYCT mRNA

NCBI chr 3:63,204,779...63,211,847
Ensembl chr 3:62,818,502...63,211,845

G

cytochrome P450, family 11, subfamily b, polypeptide 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CYP11B1 mRNA

NCBI chr 7:116,155,928...116,161,781
Ensembl chr 7:116,156,219...116,255,167

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CYP17A1 mRNA

NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
affects response to substance

2,5,2',5'-tetrachlorobiphenyl inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
CYP1A1 protein affects the susceptibility to 2,5,2',5'-tetrachlorobiphenyl

PMID:12051995 PMID:27913846

NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression
affects response to substance

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP1A2 mRNA
CYP1A2 protein affects the susceptibility to 2,5,2',5'-tetrachlorobiphenyl

PMID:21703328 PMID:27913846

NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301

G

cytochrome P450, family 1, subfamily b, polypeptide 1

affects response to substance

CYP1B1 protein affects the susceptibility to 2,5,2',5'-tetrachlorobiphenyl

NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722

G

cytochrome P450, family 20, subfamily a, polypeptide 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CYP20A1 mRNA

NCBI chr 9:67,130,222...67,179,693
Ensembl chr 9:67,130,259...67,179,692

G

cytochrome P450, family 27, subfamily b, polypeptide 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CYP27B1 mRNA

NCBI chr 7:70,333,150...70,340,006
Ensembl chr 7:70,335,061...70,340,005

G

cytochrome P450, family 2, subfamily b, polypeptide 1

increases response to substance
multiple interactions
increases expression

CYP2B1 protein results in increased susceptibility to 2,5,2',5'-tetrachlorobiphenyl
Dexamethasone inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP2B1 mRNA]; NR1I2 gene mutant form inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP2B1 protein]; NR1I2 gene mutant form promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP2B1 mRNA]; NR1I3 gene mutant form inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP2B1 mRNA]; NR1I3 gene mutant form inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP2B1 protein]; Okadaic Acid inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP2B1 mRNA]; Okadaic Acid inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP2B1 protein]
2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP2B1 mRNA; 2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP2B1 protein

PMID:10640525 PMID:23770461

NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CYP2B9 mRNA

NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615

G

cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CYP2C38 mRNA

NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

[[SULT1A1 protein co-treated with CYP2E1 protein] results in increased susceptibility to 2,5,2',5'-tetrachlorobiphenyl] which results in increased mutagenesis of HPRT1 gene; [SULT1A1 protein co-treated with CYP2E1 protein] results in increased susceptibility to 2,5,2',5'-tetrachlorobiphenyl

NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542

G

cytochrome P450, family 2, subfamily r, polypeptide 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CYP2R1 mRNA

NCBI chr 1:184,060,521...184,106,604
Ensembl chr 1:184,093,920...184,106,200

G

cytochrome P450, family 3, subfamily a, polypeptide 18

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP3A18 mRNA

NCBI chr12:10,636,294...10,684,273
Ensembl chr12:10,636,275...10,684,278

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

increases expression
multiple interactions

2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP3A23-3A1 mRNA; 2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP3A23-3A1 protein
NR1I3 gene mutant form inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP3A23-3A1 mRNA]; Okadaic Acid inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP3A23-3A1 mRNA]; Okadaic Acid inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP3A23-3A1 protein]

NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136

G

cytochrome P450, family 3, subfamily a, polypeptide 62

multiple interactions

[POR protein co-treated with CYP3A4 protein] affects the susceptibility to 2,5,2',5'-tetrachlorobiphenyl

NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397

G

cytochrome P450, family 46, subfamily a, polypeptide 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CYP46A1 mRNA

NCBI chr 6:132,242,328...132,273,788
Ensembl chr 6:132,242,328...132,273,787

G

cysteine-rich transmembrane module containing 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CYSTM1 mRNA

NCBI chr18:29,165,206...29,233,351
Ensembl chr18:29,191,731...29,232,978

G

DAB adaptor protein 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DAB1 mRNA

NCBI chr 5:123,154,360...124,279,170
Ensembl chr 5:123,905,166...124,280,115

G

dachshund family transcription factor 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DACH1 mRNA

NCBI chr15:82,095,003...82,482,272
Ensembl chr15:82,099,159...82,482,009

G

dishevelled-binding antagonist of beta-catenin 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DACT1 mRNA

NCBI chr 6:93,740,440...93,751,003
Ensembl chr 6:93,740,586...93,749,809

G

dishevelled-binding antagonist of beta-catenin 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DACT2 mRNA

NCBI chr 1:56,159,435...56,169,443
Ensembl chr 1:56,159,426...56,168,351

G

D-amino-acid oxidase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DAO mRNA

NCBI chr12:48,353,691...48,373,647
Ensembl chr12:48,354,196...48,365,784

G

death associated protein kinase 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DAPK1 mRNA

NCBI chr17:4,297,038...4,454,941
Ensembl chr17:4,297,224...4,454,778

G

DBF4 zinc finger

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DBF4 mRNA

NCBI chr 4:22,898,527...22,914,091
Ensembl chr 4:22,898,527...22,914,177

G

drebrin 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DBN1 mRNA

NCBI chr17:9,679,511...9,693,878
Ensembl chr17:9,679,628...9,693,820

G

DDB1 and CUL4 associated factor 17

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DCAF17 mRNA

NCBI chr 3:57,646,799...57,678,802
Ensembl chr 3:57,646,811...57,673,418

G

doublecortin domain containing 5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DCDC5 mRNA

NCBI chr 3:97,207,500...97,435,067
Ensembl chr 3:97,256,881...97,433,651

G

deoxycytidine kinase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DCK mRNA

NCBI chr14:20,935,442...20,952,939
Ensembl chr14:20,935,369...20,953,095

G

decapping enzyme, scavenger

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DCPS mRNA

NCBI chr 8:36,321,992...36,374,665
Ensembl chr 8:36,321,993...36,374,673

G

doublecortin

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DCX mRNA

NCBI chr X:115,098,675...115,175,515
Ensembl chr X:115,098,675...115,175,299

G

DNA damage-induced apoptosis suppressor

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DDIAS mRNA

NCBI chr 1:157,675,754...157,700,064
Ensembl chr 1:157,675,765...157,700,064

G

discoidin domain receptor tyrosine kinase 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DDR2 mRNA

NCBI chr13:88,311,639...88,436,561
Ensembl chr13:88,317,145...88,436,789

G

D-dopachrome tautomerase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DDT mRNA

NCBI chr20:13,827,153...13,829,624
Ensembl chr20:13,827,132...13,831,588

G

defensin beta 14

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DEFB14 mRNA

NCBI chr16:75,647,523...75,650,913
Ensembl chr16:75,647,680...75,648,538

G

defensin beta 17

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DEFB41 mRNA

NCBI chr 9:24,506,246...24,509,761
Ensembl chr 9:24,506,246...24,509,761

G

DEP domain containing 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DEPDC1A mRNA

NCBI chr 2:264,704,738...264,738,265
Ensembl chr 2:264,704,769...264,738,257

G

deuterosome assembly protein 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DEUP1 mRNA

NCBI chr 8:14,094,742...14,157,232
Ensembl chr 8:14,094,732...14,157,141

G

diacylglycerol kinase, gamma

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DGKG mRNA

NCBI chr11:81,971,585...82,165,111
Ensembl chr11:81,972,219...82,163,165

G

DEAH-box helicase 35

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of DHX35 mRNA

NCBI chr 3:155,297,545...155,354,857
Ensembl chr 3:155,297,566...155,356,462

G

DExH-box helicase 9

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of DHX9 mRNA

NCBI chr13:70,885,503...70,922,278
Ensembl chr13:70,885,504...70,922,245

G

disco-interacting protein 2 homolog B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DIP2B mRNA

NCBI chr 7:141,702,034...141,878,945
Ensembl chr 7:141,702,038...141,879,951

G

DIRAS family GTPase 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DIRAS2 mRNA

NCBI chr17:12,738,078...12,766,700
Ensembl chr17:12,762,752...12,763,952

G

DISC1 scaffold protein

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DISC1 mRNA

NCBI chr19:57,818,838...58,069,992
Ensembl chr19:57,820,260...58,066,152

G

dispatched RND transporter family member 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DISP2 mRNA

NCBI chr 3:110,574,383...110,589,909
Ensembl chr 3:110,574,417...110,589,921

G

dickkopf WNT signaling pathway inhibitor 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DKK4 mRNA

NCBI chr16:74,260,551...74,264,142
Ensembl chr16:74,260,551...74,264,142

G

deleted in lymphocytic leukemia, 7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DLEU7 mRNA

NCBI chr15:45,360,505...45,378,840
Ensembl chr15:45,360,503...45,376,476

G

discs large MAGUK scaffold protein 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DLG2 mRNA

NCBI chr 1:154,916,274...157,274,077
Ensembl chr 1:156,552,328...157,269,747

G

discs large MAGUK scaffold protein 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180 co-treated with APP protein modified form] results in decreased expression of DLG4 protein

NCBI chr10:56,625,845...56,655,543
Ensembl chr10:56,627,411...56,653,599

G

DLG associated protein 5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DLGAP5 mRNA

NCBI chr15:24,167,484...24,199,417
Ensembl chr15:24,167,486...24,199,341

G

dystrophin

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DMD mRNA

NCBI chr X:51,149,358...53,519,271
Ensembl chr X:51,286,737...53,519,259

G

dynein, axonemal, heavy chain 8

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DNAH8 mRNA

NCBI chr20:9,301,317...9,560,805
Ensembl chr20:9,313,271...9,560,682

G

DnaJ heat shock protein family (Hsp40) member B8

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of DNAJB8 mRNA

NCBI chr 4:120,156,640...120,159,708
Ensembl chr 4:120,156,659...120,159,265

G

DnaJ heat shock protein family (Hsp40) member C27

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DNAJC27 mRNA

NCBI chr 6:28,515,054...28,544,756
Ensembl chr 6:28,515,025...28,544,790

G

DnaJ heat shock protein family (Hsp40) member C6

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DNAJC6 mRNA

NCBI chr 5:120,330,372...120,492,515
Ensembl chr 5:120,340,646...120,492,487

G

deoxyribonuclease 2 beta

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DNASE2B mRNA

NCBI chr 2:252,436,363...252,475,506
Ensembl chr 2:252,436,332...252,451,999

G

dynamin 2

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of DNM2 mRNA

NCBI chr 8:22,458,869...22,540,649
Ensembl chr 8:22,458,899...22,540,524

G

DNA methyltransferase 3 beta

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DNMT3B mRNA

NCBI chr 3:149,131,541...149,170,061
Ensembl chr 3:149,131,785...149,208,786

G

DNA methyltransferase 3 like

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DNMT3L mRNA

NCBI chr20:11,344,513...11,359,090
Ensembl chr20:11,344,514...11,359,090

G

double C2 domain beta

affects expression

2,5,2',5'-tetrachlorobiphenyl affects the expression of DOC2B mRNA

NCBI chr10:63,921,255...63,952,944
Ensembl chr10:63,928,064...63,952,726

G

dedicator of cytokinesis 11

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DOCK11 mRNA

NCBI chr X:122,507,169...122,690,463
Ensembl chr X:122,507,374...122,690,465

G

dedicator of cytokinesis 7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DOCK7 mRNA

NCBI chr 5:117,595,194...117,780,844
Ensembl chr 5:117,596,136...117,780,777

G

docking protein 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DOK3 mRNA

NCBI chr17:9,639,064...9,644,090
Ensembl chr17:9,639,330...9,644,090

G

docking protein 5

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of DOK5 mRNA

NCBI chr 3:168,345,116...168,482,445
Ensembl chr 3:168,345,152...168,482,441

G

docking protein 6

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DOK6 mRNA

NCBI chr18:86,420,361...86,878,142
Ensembl chr18:86,420,361...86,878,142

G

double PHD fingers 3

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of DPF3 mRNA

NCBI chr 6:106,660,569...106,971,310
Ensembl chr 6:106,721,349...106,971,250

G

diphthamide biosynthesis 5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DPH5 mRNA

NCBI chr 2:218,834,034...218,866,763
Ensembl chr 2:218,834,034...218,866,761

G

dipeptidyl peptidase like 10

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DPP10 mRNA

NCBI chr13:39,430,590...41,173,706
Ensembl chr13:39,434,217...39,643,361

G

dipeptidylpeptidase 8

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of DPP8 mRNA

NCBI chr 8:70,521,782...70,576,180
Ensembl chr 8:70,522,092...70,573,424

G

dorsal inhibitory axon guidance protein

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DRAXIN mRNA

NCBI chr 5:164,913,085...164,943,012
Ensembl chr 5:164,913,906...164,927,869

G

dynein regulatory complex subunit 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DRC3 mRNA

NCBI chr10:46,712,021...46,762,276
Ensembl chr10:46,722,109...46,762,250

G

DS cell adhesion molecule

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of DSCAM mRNA

NCBI chr11:37,004,776...37,599,866
Ensembl chr11:37,004,902...37,253,776

G

DS cell adhesion molecule-like 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DSCAML1 mRNA

NCBI chr 8:49,733,835...50,056,115
Ensembl chr 8:49,737,798...50,055,560

G

DNA replication and sister chromatid cohesion 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DSCC1 mRNA

NCBI chr 7:94,759,076...94,774,787
Ensembl chr 7:94,758,800...94,774,569

G

dystrobrevin, alpha

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DTNA mRNA

NCBI chr18:14,544,725...14,671,514
Ensembl chr18:14,471,213...14,657,332

G

dystrobrevin, beta

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DTNB mRNA

NCBI chr 6:27,975,302...28,177,236
Ensembl chr 6:27,975,417...28,177,214

G

dual specificity phosphatase 14

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DUSP14 mRNA

NCBI chr10:71,363,688...71,383,602
Ensembl chr10:71,363,688...71,383,602

G

dual specificity phosphatase 19

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DUSP19 mRNA

NCBI chr 3:67,849,966...67,862,475
Ensembl chr 3:67,849,966...67,862,475

G

dishevelled segment polarity protein 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DVL3 mRNA

NCBI chr11:84,051,177...84,068,479
Ensembl chr11:84,051,078...84,068,302

G

dual specificity tyrosine phosphorylation regulated kinase 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DYRK2 mRNA

NCBI chr 7:61,785,423...61,816,775
Ensembl chr 7:61,786,309...61,798,729

G

E2F transcription factor 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of E2F2 mRNA

NCBI chr 5:154,516,611...154,540,228
Ensembl chr 5:154,522,119...154,540,265

G

E2F transcription factor 7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of E2F7 mRNA

NCBI chr 7:53,275,659...53,318,261
Ensembl chr 7:53,275,676...53,316,481

G

E2F transcription factor 8

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of E2F8 mRNA

NCBI chr 1:104,185,436...104,203,683
Ensembl chr 1:104,187,100...104,202,591

G

EBF transcription factor 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EBF1 mRNA

NCBI chr10:23,654,849...24,051,627
Ensembl chr10:23,661,013...24,050,209

G

EBF transcription factor 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EBF2 mRNA

NCBI chr15:43,905,099...44,103,742
Ensembl chr15:43,905,099...44,103,742

G

EBF transcription factor 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EBF3 mRNA

NCBI chr 1:209,523,153...209,641,143
Ensembl chr 1:209,523,157...209,641,123

G

epithelial cell transforming 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ECT2 mRNA

NCBI chr 2:112,769,385...112,831,476
Ensembl chr 2:112,769,385...112,831,476

G

eukaryotic elongation factor-2 kinase

increases expression
multiple interactions

2,5,2',5'-tetrachlorobiphenyl results in increased expression of EEF2K mRNA
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of EEF2K mRNA

PMID:23829299 PMID:25510870

NCBI chr 1:190,780,211...190,839,926
Ensembl chr 1:190,780,236...190,842,324

G

EF-hand calcium binding domain 11

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EFCAB11 mRNA

NCBI chr 6:123,742,971...123,894,714
Ensembl chr 6:123,743,064...123,894,826

G

ephrin A3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of EFNA3 mRNA

NCBI chr 2:188,636,304...188,645,302
Ensembl chr 2:188,637,852...188,645,196

G

epidermal growth factor

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EGF mRNA

NCBI chr 2:68,820,616...68,895,537

G

eukaryotic translation initiation factor 4E binding protein 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EIF4EBP3 mRNA

NCBI chr18:29,490,981...29,492,727
Ensembl chr18:29,386,809...29,492,718

G

ELAV like RNA binding protein 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ELAVL2 mRNA

NCBI chr 5:109,499,410...109,651,829
Ensembl chr 5:109,499,408...109,651,730

G

E74 like ETS transcription factor 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ELF4 mRNA

NCBI chr X:135,239,626...135,284,330
Ensembl chr X:135,240,451...135,250,519

G

ETS transcription factor ELK4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ELK4 mRNA

NCBI chr13:48,788,262...48,813,267
Ensembl chr13:48,790,509...48,813,260

G

elongation factor for RNA polymerase II 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ELL3 mRNA

NCBI chr 3:113,400,395...113,405,869
Ensembl chr 3:113,401,734...113,405,829

G

engulfment and cell motility 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ELMO3 mRNA

NCBI chr19:37,260,330...37,264,832
Ensembl chr19:37,260,469...37,264,829

G

essential meiotic structure-specific endonuclease 1

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of EME1 mRNA

NCBI chr10:82,366,820...82,375,510
Ensembl chr10:82,367,084...82,374,171

G

ectodermal-neural cortex 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ENC1 mRNA

NCBI chr 2:28,049,217...28,061,023
Ensembl chr 2:28,049,217...28,061,029

G

enolase 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ENO2 mRNA

NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ENPP2 mRNA

NCBI chr 7:94,479,931...94,563,086
Ensembl chr 7:94,480,396...94,563,001

G

ectonucleoside triphosphate diphosphohydrolase 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ENTPD4 mRNA

NCBI chr15:51,222,954...51,250,787
Ensembl chr15:51,222,954...51,250,787

G

eomesodermin

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EOMES mRNA

NCBI chr 8:127,144,367...127,152,618
Ensembl chr 8:127,144,903...127,151,493

G

E1A binding protein p400

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EP400 mRNA

NCBI chr12:51,948,650...52,055,274
Ensembl chr12:51,948,650...52,055,271

G

erythrocyte membrane protein band 4.1-like 3

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of EPB41L3 mRNA

NCBI chr 9:117,314,935...117,666,408
Ensembl chr 9:117,538,009...117,666,410

G

erythrocyte membrane protein band 4.1 like 5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of EPB41L5 mRNA

NCBI chr13:35,622,472...35,673,449
Ensembl chr13:35,580,098...35,668,968

G

EPH receptor A5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of EPHA5 mRNA

NCBI chr14:25,589,312...25,958,258
Ensembl chr14:25,589,762...25,958,227

G

epididymal peptidase inhibitor

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of EPPIN mRNA

NCBI chr 3:161,043,761...161,050,550
Ensembl chr 3:161,041,727...161,050,557

G

EPS8-like 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of EPS8L2 mRNA

NCBI chr 1:214,327,992...214,353,466
Ensembl chr 1:214,328,071...214,353,461

G

ERCC excision repair 6 like, spindle assembly checkpoint helicase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ERCC6L mRNA

NCBI chr X:72,018,373...72,034,140
Ensembl chr X:72,018,373...72,034,099

G

exoribonuclease 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ERI1 mRNA

NCBI chr16:60,307,148...60,327,237
Ensembl chr16:60,307,148...60,327,236

G

ERI1 exoribonuclease family member 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ERI2 mRNA

NCBI chr 1:189,540,145...189,549,891
Ensembl chr 1:189,540,145...189,549,891

G

establishment of sister chromatid cohesion N-acetyltransferase 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ESCO1 mRNA

NCBI chr18:1,789,796...1,857,271
Ensembl chr18:1,789,900...1,828,606

G

establishment of sister chromatid cohesion N-acetyltransferase 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ESCO2 mRNA

NCBI chr15:42,500,929...42,519,019
Ensembl chr15:42,500,929...42,518,855

G

extra spindle pole bodies like 1, separase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ESPL1 mRNA

NCBI chr 7:143,896,890...143,923,868
Ensembl chr 7:143,897,014...143,923,868

G

estrogen-related receptor beta

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ESRRB mRNA

NCBI chr 6:110,360,940...110,458,406
Ensembl chr 6:110,410,141...110,455,906

G

extended synaptotagmin 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ESYT3 mRNA

NCBI chr 8:107,555,417...107,602,414
Ensembl chr 8:107,555,277...107,602,263

G

ethanolamine-phosphate phospho-lyase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ETNPPL mRNA

NCBI chr 2:235,738,377...235,760,351
Ensembl chr 2:235,738,416...235,760,352

G

ETS variant transcription factor 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ETV1 mRNA

NCBI chr 6:58,467,215...58,558,640
Ensembl chr 6:58,467,254...58,558,631

G

exonuclease 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EXO1 mRNA

NCBI chr13:93,936,989...93,962,749
Ensembl chr13:93,939,022...93,960,342

G

exocyst complex component 6B

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of EXOC6B mRNA

NCBI chr 4:116,314,695...116,786,466
Ensembl chr 4:116,314,695...116,786,424

G

exosome component 2

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of EXOSC2 mRNA

NCBI chr 3:10,151,734...10,161,997
Ensembl chr 3:10,151,284...10,161,989

G

enhancer of zeste 2 polycomb repressive complex 2 subunit

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EZH2 mRNA

NCBI chr 4:77,284,404...77,347,011
Ensembl chr 4:77,284,404...77,347,011

G

coagulation factor II

affects expression

2,5,2',5'-tetrachlorobiphenyl affects the expression of F2 mRNA

NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031

G

coagulation factor II (thrombin) receptor

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of F2R mRNA

NCBI chr 2:26,118,760...26,135,340
Ensembl chr 2:26,118,760...26,135,340

G

fatty acid binding protein 9

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FABP9 mRNA

NCBI chr 2:93,803,503...93,807,069
Ensembl chr 2:93,803,449...93,807,069

G

Fas apoptotic inhibitory molecule 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FAIM2 mRNA

NCBI chr 7:141,158,769...141,185,781
Ensembl chr 7:141,157,963...141,185,710

G

family with sequence similarity 13, member C

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FAM13C mRNA

NCBI chr20:19,358,869...19,470,212
Ensembl chr20:19,360,230...19,479,325

G

family with sequence similarity 155, member B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of TMEM28 mRNA

NCBI chr X:69,579,968...69,605,032
Ensembl chr X:69,580,015...69,605,032

G

family with sequence similarity 160, member A1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FAM160A1 mRNA

NCBI chr 2:184,684,851...184,993,350
Ensembl chr 2:184,941,700...185,168,773

G

family with sequence similarity 217, member B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FAM217B mRNA

NCBI chr 3:173,953,752...173,961,615
Ensembl chr 3:173,953,869...173,963,629

G

family with sequence similarity 234, member A

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of FAM234A mRNA

G

family with sequence similarity 43, member B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FAM43B mRNA

NCBI chr 5:156,809,705...156,813,352
Ensembl chr 5:156,810,658...156,811,650

G

family with sequence similarity 53, member B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FAM53B mRNA

NCBI chr 1:204,714,468...204,805,738
Ensembl chr 1:204,714,473...204,817,080

G

FA complementation group A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FANCA mRNA

NCBI chr19:56,067,548...56,126,075
Ensembl chr19:56,067,548...56,126,063

G

FA complementation group D2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FANCD2 mRNA

NCBI chr 4:145,489,869...145,551,479
Ensembl chr 4:145,489,869...145,551,479

G

FA complementation group I

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FANCI mRNA

NCBI chr 1:141,116,565...141,172,997
Ensembl chr 1:141,120,166...141,172,483

G

phenylalanyl-tRNA synthetase subunit alpha

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FARSA mRNA

NCBI chr19:25,969,255...25,978,777
Ensembl chr19:25,969,255...25,978,776

G

FAST kinase domains 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FASTKD2 mRNA

NCBI chr 9:70,448,386...70,471,420
Ensembl chr 9:70,450,444...70,470,550

G

FAT atypical cadherin 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FAT2 mRNA

NCBI chr10:40,583,025...40,682,598
Ensembl chr10:40,584,403...40,657,861

G

FAT atypical cadherin 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FAT3 mRNA

NCBI chr 8:14,417,039...15,011,596
Ensembl chr 8:14,417,584...14,880,644

G

fibulin 1

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of FBLN1 mRNA

NCBI chr 7:126,096,793...126,176,468
Ensembl chr 7:126,096,793...126,176,468

G

fibulin 5

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of FBLN5 mRNA

NCBI chr 6:125,644,797...125,723,957
Ensembl chr 6:125,644,804...125,723,944

G

F-box protein 5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FBXO5 mRNA

NCBI chr 1:42,461,277...42,467,646
Ensembl chr 1:42,461,291...42,467,586

G

Fc fragment of IgG binding protein-like 1

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of FCGBPL1 mRNA

NCBI chr 1:85,058,541...85,096,492
Ensembl chr 1:85,058,548...85,096,346

G

Fc fragment of IgG receptor Ia

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FCGR1 mRNA

NCBI chr 2:198,430,536...198,439,453
Ensembl chr 2:198,430,530...198,458,041

G

Fc receptor-like 5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FCRL5 mRNA

NCBI chr 2:186,776,466...186,797,900
Ensembl chr 2:186,776,605...186,808,078

G

fer-1-like family member 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FER1L4 mRNA

NCBI chr 3:151,564,604...151,600,140
Ensembl chr 3:151,564,604...151,600,140

G

fasciculation and elongation protein zeta 2

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of FEZ2 mRNA

NCBI chr 6:963,903...1,003,955
Ensembl chr 6:963,907...1,004,001

G

FYVE, RhoGEF and PH domain containing 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FGD1 mRNA

NCBI chr  X:20,100,942...20,143,871
Ensembl chr  X:20,216,587...20,225,955
Ensembl chr  X:20,216,587...20,225,955

G

FYVE, RhoGEF and PH domain containing 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FGD4 mRNA

NCBI chr11:88,699,222...88,796,677
Ensembl chr11:88,699,222...88,796,677

G

fibroblast growth factor 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FGF1 mRNA

NCBI chr18:32,273,830...32,359,831
Ensembl chr18:32,273,770...32,359,824

G

fibroblast growth factor 12

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FGF12 mRNA

NCBI chr11:75,606,360...76,171,078
Ensembl chr11:75,905,443...76,168,989

G

fibroblast growth factor 14

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FGF14 mRNA

NCBI chr15:110,382,274...111,077,027
Ensembl chr15:110,385,217...110,612,681

G

fibroblast growth factor 21

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FGF21 mRNA

NCBI chr 1:101,595,579...101,596,822
Ensembl chr 1:101,595,579...101,596,822

G

fibroblast growth factor 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FGF3 mRNA

NCBI chr 1:218,003,018...218,006,942
Ensembl chr 1:218,003,018...218,006,942

G

fibroblast growth factor 6

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FGF6 mRNA

NCBI chr 4:159,563,798...159,572,333
Ensembl chr 4:159,563,798...159,572,333

G

fibroblast growth factor 7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FGF7 mRNA

NCBI chr 3:118,315,859...118,368,464
Ensembl chr 3:118,317,761...118,366,872

G

FGGY carbohydrate kinase domain containing

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FGGY mRNA

NCBI chr 5:114,516,860...114,901,571
Ensembl chr 5:114,516,889...114,901,564

G

fidgetin-like 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FIGNL1 mRNA

NCBI chr14:91,895,902...91,904,474
Ensembl chr14:91,895,909...91,904,433

G

fat storage-inducing transmembrane protein 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FITM1 mRNA

NCBI chr15:34,251,805...34,253,074
Ensembl chr15:34,251,606...34,253,073

G

FKBP prolyl isomerase 1A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FKBP1A mRNA

NCBI chr 3:147,042,944...147,062,725
Ensembl chr 3:147,042,944...147,062,724

G

filamin A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FLNA mRNA

NCBI chr X:156,460,785...156,487,245
Ensembl chr X:156,463,953...156,487,245

G

Fms related receptor tyrosine kinase 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FLT1 mRNA

NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905

G

Fms related receptor tyrosine kinase 4

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of FLT4 mRNA

NCBI chr10:35,078,782...35,120,296
Ensembl chr10:35,078,726...35,121,599

G

fibronectin 1

decreases expression
multiple interactions

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of FN1 mRNA
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FN1 mRNA

PMID:23829299 PMID:25510870

NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078

G

fructosamine-3-kinase-related protein

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of FN3KRP mRNA

NCBI chr10:110,614,739...110,622,625
Ensembl chr10:110,614,713...110,623,519

G

formin binding protein 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FNBP1 mRNA

NCBI chr 3:9,865,657...9,936,333
Ensembl chr 3:9,861,237...9,936,405

G

formin binding protein 1-like

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FNBP1L mRNA

NCBI chr 2:226,691,435...226,742,081
Ensembl chr 2:226,688,844...226,779,440

G

formin binding protein 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FNBP4 mRNA

NCBI chr 3:79,570,610...79,610,122
Ensembl chr 3:79,570,625...79,610,454

G

fibronectin type III domain containing 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FNDC1 mRNA

NCBI chr 1:47,605,211...47,687,499
Ensembl chr 1:47,605,262...47,687,504

G

farnesyltransferase, CAAX box, beta

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of FNTB mRNA

NCBI chr 6:99,883,959...99,966,988
Ensembl chr 6:99,883,959...99,966,988

G

folate receptor alpha

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FOLR1 mRNA

NCBI chr 1:166,934,457...166,945,864
Ensembl chr 1:166,934,460...166,943,592

G

forkhead box A3

affects expression

2,5,2',5'-tetrachlorobiphenyl affects the expression of FOXA3 mRNA

NCBI chr 1:79,921,292...79,930,219
Ensembl chr 1:79,920,752...79,930,263

G

forkhead box L2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FOXL2 mRNA

NCBI chr 8:107,194,492...107,197,644
Ensembl chr 8:107,194,551...107,195,675

G

forkhead box M1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FOXM1 mRNA

NCBI chr 4:161,685,236...161,697,633
Ensembl chr 4:161,685,258...161,696,305

G

forkhead box P1

decreases expression
multiple interactions

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of FOXP1 mRNA
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FOXP1 mRNA

PMID:23829299 PMID:25510870

NCBI chr 4:131,362,178...131,963,466
Ensembl chr 4:131,366,744...131,694,755

G

forkhead box P2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FOXP2 mRNA

NCBI chr 4:41,364,441...41,944,685
Ensembl chr 4:41,364,441...41,942,023

G

FRAS1 related extracellular matrix 3

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of FREM3 mRNA

NCBI chr19:30,973,329...31,032,331
Ensembl chr19:30,973,329...31,031,817

G

FERM domain containing 4A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FRMD4A mRNA

NCBI chr17:77,642,302...77,918,210

G

FERM and PDZ domain containing 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FRMPD3 mRNA

NCBI chr X:111,689,587...111,778,943

G

FERM and PDZ domain containing 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FRMPD4 mRNA

NCBI chr X:27,231,648...28,206,890
Ensembl chr X:28,072,826...28,204,260

G

FRY microtubule binding protein

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FRY mRNA

NCBI chr12:5,573,729...5,822,874
Ensembl chr12:5,573,729...5,822,874

G

FRY like transcription coactivator

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FRYL mRNA

NCBI chr14:37,551,109...37,757,511
Ensembl chr14:37,551,940...37,756,149

G

fascin actin-bundling protein 2, retinal

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of FSCN2 mRNA

NCBI chr10:109,528,307...109,540,675
Ensembl chr10:109,533,487...109,540,026

G

FtsJ RNA 2'-O-methyltransferase 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FTSJ1 mRNA

NCBI chr X:14,993,685...15,006,010
Ensembl chr X:14,994,016...15,002,074

G

FUN14 domain containing 1

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of FUNDC1 mRNA

NCBI chr X:5,549,468...5,566,125
Ensembl chr X:5,549,419...5,566,127

G

fucose mutarotase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FUOM mRNA

NCBI chr 1:212,563,714...212,568,224
Ensembl chr 1:212,563,714...212,568,224

G

fucosyltransferase 7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FUT7 mRNA

NCBI chr 3:2,637,281...2,646,497
Ensembl chr 3:2,642,531...2,646,648

G

FXYD domain-containing ion transport regulator 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FXYD1 mRNA

NCBI chr 1:89,484,197...89,488,279
Ensembl chr 1:89,484,199...89,488,223

G

FXYD domain-containing ion transport regulator 4

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of FXYD4 mRNA

NCBI chr 4:149,984,206...149,988,744
Ensembl chr 4:149,984,206...149,988,295

G

G2/M-phase specific E3 ubiquitin protein ligase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of G2E3 mRNA

NCBI chr 6:72,092,148...72,123,878
Ensembl chr 6:72,092,194...72,122,497

G

alpha glucosidase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GAA mRNA

NCBI chr10:108,395,873...108,412,999
Ensembl chr10:108,395,860...108,413,059

G

GA binding protein transcription factor subunit beta 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GABPB1 mRNA

NCBI chr 3:119,091,739...119,135,391
Ensembl chr 3:119,091,744...119,135,391

G

gamma-aminobutyric acid type A receptor subunit alpha 1

multiple interactions

[2,5,2',5'-tetrachlorobiphenyl co-treated with gamma-Aminobutyric Acid] binds to and results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]

NCBI chr10:27,310,718...27,371,802
Ensembl chr10:27,310,725...27,366,665

G

gamma-aminobutyric acid type A receptor subunit beta 2

multiple interactions

[2,5,2',5'-tetrachlorobiphenyl co-treated with gamma-Aminobutyric Acid] binds to and results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]

NCBI chr10:27,973,694...28,193,072
Ensembl chr10:27,973,681...28,187,565

G

gamma-aminobutyric acid type A receptor subunit gamma 2

multiple interactions

[2,5,2',5'-tetrachlorobiphenyl co-treated with gamma-Aminobutyric Acid] binds to and results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]

NCBI chr10:27,090,913...27,179,786
Ensembl chr10:27,092,827...27,179,900

G

gamma-aminobutyric acid type A receptor subunit pi

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GABRP mRNA

NCBI chr10:18,484,257...18,510,604
Ensembl chr10:18,485,514...18,506,337

G

glutamate decarboxylase-like 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GADL1 mRNA

NCBI chr 8:123,989,822...124,301,366

G

galactosamine (N-acetyl)-6-sulfatase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GALNS mRNA

NCBI chr19:55,391,004...55,423,328
Ensembl chr19:55,389,462...55,423,150

G

polypeptide N-acetylgalactosaminyltransferase 15

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GALNT15 mRNA

NCBI chr16:8,127,599...8,178,101
Ensembl chr16:8,128,689...8,177,841

G

polypeptide N-acetylgalactosaminyltransferase 17

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GALNT17 mRNA

NCBI chr12:28,381,879...29,268,457
Ensembl chr12:28,381,982...29,268,073

G

polypeptide N-acetylgalactosaminyltransferase-like 6

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GALNTL6 mRNA

NCBI chr16:34,551,052...35,803,840
Ensembl chr16:35,573,058...35,802,979

G

galanin receptor 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GALR1 mRNA

NCBI chr18:79,243,009...79,258,570
Ensembl chr18:79,243,009...79,258,570

G

glyceraldehyde-3-phosphate dehydrogenase, spermatogenic

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GAPDHS mRNA

NCBI chr 1:89,180,063...89,195,347
Ensembl chr 1:89,180,063...89,194,602

G

GAR1 ribonucleoprotein

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GAR1 mRNA

NCBI chr 2:235,250,453...235,258,464
Ensembl chr 2:235,250,453...235,257,731

G

GTPase activating Rap/RanGAP domain-like 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GARNL3 mRNA

NCBI chr 3:12,034,131...12,176,591
Ensembl chr 3:12,034,413...12,155,098

G

growth arrest specific 7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GAS7 mRNA

NCBI chr10:54,010,723...54,240,805
Ensembl chr10:54,126,486...54,236,476

G

GATA binding protein 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GATA1 mRNA

NCBI chr X:15,273,937...15,281,759
Ensembl chr X:15,378,789...15,382,066

G

GATA binding protein 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GATA3 mRNA

NCBI chr17:72,419,752...72,452,043
Ensembl chr17:72,429,618...72,450,681

G

GATA zinc finger domain containing 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GATAD1 mRNA

NCBI chr 4:27,647,005...27,658,533
Ensembl chr 4:27,647,335...27,657,167

G

guanylate binding protein 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GBP4 mRNA

NCBI chr 2:248,249,232...248,263,104
Ensembl chr 2:248,249,468...248,263,168

G

gastrulation brain homeobox 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GBX1 mRNA

NCBI chr 4:7,173,961...7,200,752
Ensembl chr 4:7,173,961...7,200,752

G

glutamate cysteine ligase, modifier subunit

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of GCLM mRNA

NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874

G

growth differentiation factor 11

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of GDF11 mRNA

NCBI chr 7:3,306,863...3,315,856
Ensembl chr 7:3,306,863...3,315,856

G

growth differentiation factor 6

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GDF6 mRNA

NCBI chr 5:23,056,345...23,072,666
Ensembl chr 5:23,056,347...23,074,599

G

glycerophosphodiester phosphodiesterase domain containing 5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GDPD5 mRNA

NCBI chr 1:164,337,176...164,418,056
Ensembl chr 1:164,380,577...164,418,593

G

GDP-D-glucose phosphorylase 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GDPGP1 mRNA

NCBI chr 1:142,020,696...142,028,775

G

gem (nuclear organelle) associated protein 6

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GEMIN6 mRNA

NCBI chr 6:2,907,040...2,911,577
Ensembl chr 6:2,907,145...2,911,559

G

glucose-fructose oxidoreductase domain containing 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GFOD1 mRNA

NCBI chr17:23,818,370...23,924,393
Ensembl chr17:23,823,632...23,923,792

G

GDNF family receptor alpha 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GFRA2 mRNA

NCBI chr15:52,557,004...52,648,984
Ensembl chr15:52,557,607...52,648,972

G

gamma-glutamylamine cyclotransferase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GGACT mRNA

NCBI chr15:109,307,683...109,336,779
Ensembl chr15:109,307,904...109,316,953

G

gametogenetin binding protein 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GGNBP1 mRNA

NCBI chr20:5,618,973...5,625,320
Ensembl chr20:5,619,012...5,625,320

G

gamma-glutamyl transferase 6

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GGT6 mRNA

NCBI chr10:58,995,253...58,998,431
Ensembl chr10:58,995,556...58,998,033

G

GTPase, IMAP family member 8

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GIMAP8 mRNA

NCBI chr 4:78,283,356...78,294,838
Ensembl chr 4:78,283,026...78,294,845

G

GINS complex subunit 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GINS1 mRNA

NCBI chr 3:146,695,366...146,716,787
Ensembl chr 3:146,695,344...146,716,816

G

GIPC PDZ domain containing family, member 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GIPC2 mRNA

NCBI chr 2:257,293,161...257,377,982
Ensembl chr 2:257,293,167...257,376,756

G

gap junction protein, gamma 2

decreases expression

2,5,2',5'-tetrachlorobiphenyl results in decreased expression of GJC2 mRNA

NCBI chr10:45,526,740...45,535,520
Ensembl chr10:45,526,745...45,534,570

G

gastrokine 1

increases expression

2,5,2',5'-tetrachlorobiphenyl results in increased expression of GKN1 mRNA

NCBI chr 4:119,143,070...119,148,358
Ensembl chr 4:119,143,070...119,148,358

G

glucuronic acid epimerase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GLCE mRNA

NCBI chr 8:67,006,588...67,073,723
Ensembl chr 8:67,006,592...67,040,005

G

GLI family zinc finger 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GLI2 mRNA

NCBI chr13:34,829,021...35,049,172
Ensembl chr13:34,829,139...35,048,444

G

glutaminase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GLS mRNA

NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872

G

glycosyltransferase 1 domain containing 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GLT1D1 mRNA

NCBI chr12:32,666,664...32,749,617
Ensembl chr12:32,666,635...32,740,732

G

glycolipid transfer protein

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GLTP mRNA

NCBI chr12:47,667,556...47,687,708
Ensembl chr12:47,667,556...47,687,707

G

glucocorticoid modulatory element binding protein 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GMEB1 mRNA

NCBI chr 5:150,408,075...150,449,252
Ensembl chr 5:150,405,918...150,439,959

G

GDP-mannose pyrophosphorylase A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GMPPA mRNA

NCBI chr 9:82,632,267...82,639,811
Ensembl chr 9:82,632,230...82,639,821

G

guanine monophosphate synthase

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GMPS mRNA

NCBI chr 2:154,555,967...154,590,662
Ensembl chr 2:154,555,871...154,590,662

G

G protein subunit alpha L

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GNAL mRNA

NCBI chr18:62,805,406...62,946,133
Ensembl chr18:62,805,410...62,944,630

G

G protein subunit beta 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GNB3 mRNA

NCBI chr 4:157,352,558...157,359,237
Ensembl chr 4:157,352,372...157,358,262

G

G protein subunit gamma 13

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GNG13 mRNA

NCBI chr10:15,088,935...15,090,839
Ensembl chr10:15,088,935...15,090,839

G

G protein subunit gamma 7

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GNG7 mRNA

NCBI chr 7:11,565,740...11,629,519
Ensembl chr 7:11,582,984...11,628,929

G

G protein subunit gamma 8

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GNG8 mRNA

NCBI chr 1:78,818,360...78,822,224
Ensembl chr 1:78,818,404...78,822,224

G

glypican 2

increases expression
multiple interactions

2,5,2',5'-tetrachlorobiphenyl results in increased expression of GPC2 mRNA
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GPC2 mRNA

PMID:23829299 PMID:25510870

NCBI chr12:19,593,041...19,599,374
Ensembl chr12:19,593,041...19,599,374

G

glypican 5

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GPC5 mRNA

NCBI chr15:100,283,131...101,776,838

G

G protein-coupled receptor 137C

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GPR137C mRNA

NCBI chr15:19,547,783...19,615,717
Ensembl chr15:19,547,871...19,614,805

G

G protein-coupled receptor 37

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GPR37 mRNA

NCBI chr 4:51,822,163...51,844,228
Ensembl chr 4:51,822,153...51,844,331

G

G protein-coupled receptor 75

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GPR75 mRNA

NCBI chr14:115,270,452...115,278,510
Ensembl chr14:115,275,894...115,278,503

G

G protein-coupled receptor 82

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GPR82 mRNA

NCBI chr X:9,992,832...10,001,036
Ensembl chr X:9,998,415...9,999,401

G

G-protein coupled receptor 88

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GPR88 mRNA

NCBI chr 2:219,258,346...219,263,819
Ensembl chr 2:219,258,347...219,262,901

G

G protein-coupled receptor, class C, group 5, member B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GPRC5B mRNA

NCBI chr 1:188,688,743...188,713,724
Ensembl chr 1:188,688,743...188,713,280

G

G protein-coupled receptor, class C, group 5, member C

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GPRC5C mRNA

NCBI chr10:103,395,222...103,417,360
Ensembl chr10:103,395,511...103,417,358

G

GPRIN family member 3

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GPRIN3 mRNA

NCBI chr 4:89,690,678...89,778,302
Ensembl chr 4:89,693,280...89,695,928

G

glutathione peroxidase 4

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GPX4 mRNA

NCBI chr 7:12,516,357...12,519,154
Ensembl chr 7:12,516,352...12,519,154

G

glutathione peroxidase 6

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GPX6 mRNA

NCBI chr17:45,439,268...45,446,952
Ensembl chr17:45,439,268...45,446,907

G

GRAM domain containing 2A

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GRAMD2 mRNA

NCBI chr 8:64,503,058...64,539,149
Ensembl chr 8:64,531,594...64,539,367

G

GRB2-related adaptor protein 2

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GRAP2 mRNA

NCBI chr 7:121,791,330...121,864,835
Ensembl chr 7:121,841,855...121,864,679

G

growth regulating estrogen receptor binding 1

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GREB1 mRNA

NCBI chr 6:41,932,941...42,002,770
Ensembl chr 6:41,932,244...42,002,819

G

glutamate ionotropic receptor NMDA type subunit 2A

increases expression
multiple interactions

2,5,2',5'-tetrachlorobiphenyl results in increased expression of GRIN2A protein
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GRIN2A mRNA

PMID:20297801 PMID:25510870

NCBI chr10:5,707,806...6,123,568
Ensembl chr10:5,930,298...6,119,990

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GRIN2B mRNA

NCBI chr 4:169,541,620...170,000,216
Ensembl chr 4:169,560,387...169,999,873

G

glutamate ionotropic receptor NMDA type subunit 2C

multiple interactions

[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GRIN2C mRNA

NCBI chr10:103,798,290...103,816,923
Ensembl chr10:103,798,291...103,816,287